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Overview of
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This workbook is part of a series
intended to educate programme
planners, managers, staff and other
decision-makers about the evaluation
of services and systems for the
treatment of psychoactive substance
use disorders. The objective of this
series is to enhance their capacity for
carrying out evaluation activities. The
broader goal of the workbooks is to
enhance treatment efficiency and cost-
effectiveness using the information
that comes from these evaluation
activities.
This workbook considers outcome
evaluation. Outcome evaluations
measure the extent to which clients
of services, or networks of services
for substance use disorders, change
following participation in treatment.
The workbook offers advice on
measuring the changes and attributing
change to programme involvement.
7Workbook 7  •  Outcome Evaluations
WHO/MSD/MSB 00.2h
What is an outcome
evaluation?
Outcome evaluations measure how clients
and their circumstances change, and
whether the treatment experience has
been a factor in causing this change. In
other words, outcome evaluations aim to
assess treatment effectiveness.
Some questions that might be addressed in
outcome evaluations include:
• Have clients’ quality of life improved fol-
lowing treatment?
• Has there been a reduction in the quan-
tity/frequency of PSU following treat-
ment?
• Is client participation in our treatment
programme “responsible” for their im-
provement?
There are a number of ways to design out-
come evaluation and measure these types
of changes. The most widely-praised way
to measure client improvement and infer
causality  (i.e., to infer that your
programme is responsible for the observed
client improvement) is the experimental
approach. This is sometimes called a
“randomised-controlled trial”. Other meth-
ods for studying outcome include the
“comparison group approach” and the
“pre-post design.” All these methods are
described later in this workbook.
Outcome evaluations provide
information on how well your
programme is accomplishing its goals.
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You may be saying to yourself, “I know that
my treatment programme is effective be-
cause I have seen many people get better
following participation. Why do I need to do
an outcome evaluation?” The answer is rela-
tively simple. If clients get better following
treatment, it does not necessarily mean that
your treatment caused these changes. Think
about it. People change for many reasons.
Improvements in your clients’ PSU may be
the result of something completely different
from your programme. Common other rea-
sons for improvement, beyond the effects of
treatment itself, include:
• Other things that happened
during and after treatment
Clients may have found or lost an important
interpersonal relationship; found or lost a job;
moved to a new neighbourhood; or become
involved with a self-help group. All of these
events could influence their PSU indepen-
dently of the effects of treatment. Such events
can also interact with treatment effects in
complex ways. For example, the clients who
have done well may be those who experi-
enced other positive life events.
Why do an outcome
evaluation?
• Client maturation
Over time, many people grow out of their
problems due to age-related changes. This
is particularly so for adolescents whose PSU
tends to decrease as they reach young adult-
hood.
• Natural variation or
regression
Although many clients of services for PSU
disorders, lead disruptive lives, they also have
periods of relative stability when they cut
down or eliminate their PSU. Any changes
in the behaviour and circumstances between
two periods of time may simply reflect “nor-
mal” variations rather than the effects of an
intervention. Some of those who enter treat-
ment during a particularly disruptive period
can be expected to change for the better
without treatment, even if temporarily.
For these reasons, outcome studies go be-
yond merely describing positive changes in
clients. They attempt to demonstrate scien-
tifically whether your treatment process has
caused any client changes that occur.
If clients get
better following
treatment, it
does not
necessarily
mean that your
treatment
caused these
changes.
If your programme is typical, several groups of people would be interested to know whether
your treatments are actually effective.
• Your clients
• Their family members
• Your treatment staff
• Employers of clients
• Criminal justice system
• Health insurers or other payers for your treatment services
• Government organisations
• General community members
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How to do an
outcome evaluation?
Your choice of
designs should
be influenced
by the
resources you
have available.
Each of these designs are described below.
After reading this workbook, you must
make your choice among these design op-
tions. In general, pre-post comparison is the
least scientifically rigorous design, compari-
son group designs are “moderate” in their
scientific rigour, and randomised controlled
trials use the strongest design. However,
randomised controlled trials and compari-
Outcome evaluation is based on a quantitative approach. It typically uses one of three de-
signs:
• randomised controlled trial
• comparison group
• pre-post comparison
This design option uses two or more groups
of clients who are randomly assigned to ei-
ther the treatment in question or to a plausible
alternative. Members of both groups receive
the same pre-treatment and post-treatment
assessments. Because the randomisation pro-
cess makes it equally likely that any one client
will be assigned to one group or the other,
with a sufficient number of participants this
design controls for pre-treatment individual
differences in clients (e.g., PSU frequency,
motivation for treatment) and other events that
might happen during treatment.
Randomised controlled trials can compare many
things, including different types of treatment, (e.g.,
pharmacotherapy vs. psychotherapy); different
son group designs are more resource-inten-
sive and complicated to conduct than pre-
post comparisons. Your choice of designs
should be influenced by the resources you
have available. After reading this material,
you must carefully consider the practical
realities of implementing each type of de-
sign in your programme setting.
intensities of the same treatment (e.g. short vs.
long-term); different strategies for delivering the
same treatment (e.g., group vs. individual); and
different settings (e.g., inpatient vs. outpatient).
Other comparisons involve people who received
no treatment vs. people who receive treatment.
A significant strength of randomised controlled
trials is that they can control for most competing
explanations for improvement following treat-
ment (e.g., other events that happened during
treatment). However, there are many technical
and logistical problems to overcome in the
proper design and conduct of these evaluations.
Consultation with an evaluator experienced
with randomised controlled trials is recom-
mended if you are considering this design.
Method 1:
Randomised controlled trial tesign
...clients are
randomly
assigned (like
the flip of a
coin) to either
the treatment in
question or to a
plausible
alternative.
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This design option is similar to the
randomised design except the comparison
group is deliberately rather than randomly
chosen. Comparison groups are chosen so
that clients are as similar as possible to
those in the treatment service or system
being evaluated. Statistical methods are
used to control for any remaining differ-
ences (e.g., differences in client age). The
types of treatment and alternative condi-
tions featured in comparison group evalu-
ations are similar to those noted above in
connection with experimental evaluations
(i.e., comparisons treatment types or in-
tensity).
at intake may ask about quantity and fre-
quency of PSU over the past 90 days.
Exactly the same questions would be
asked of clients six months following dis-
charge. With a pre-post design, clients may
be re-contacted on more than one occa-
sion (e.g., six months, 12 months, 18
months, and 24 months). In this case, the
evaluation is called a time-series design.
While this extended design is especially
helpful in showing the stability of outcomes
being achieved, an extra effort is required
to maintain contact with the sample of cli-
ents being followed-up.
The first case report located at the end of
this workbook (by Formigoni and
Marques) provides an example of a
randomised controlled trial design. In this
evaluation, individual and group cognitive-
behavioural treatments were compared
using random assignment to treatment con-
ditions.
Method 2:
Comparison group designs
The success
of the
evaluation
depends on
how similar
the two
groups are at
the beginning
of the
evaluation.
The extent to which comparison group studies
successfully control for the various competing
explanation factors varies with the types of ser-
vices and client groups involved. The “success”
of the evaluation depends on how similar the two
groups are at the beginning of the evaluation. For
example, different types of clients may have dif-
ferent reasons for their choice of treatment
programme. Similar to randomised controlled
trials, there are many technical and logistical
problems to overcome in the proper design and
conduct of these evaluations. Consultation with
an evaluator experienced in comparison group
evaluations is recommended if you are consid-
ering this design.
This design option is not as complex as
experimental and comparison group
evaluations. It is more realistic for treat-
ment services or systems with limited ex-
perience and/or resources. Although pre-
post designs are less scientifically
rigorous, they can produce useful results
for purposes of accountability and pro-
gramme improvement.
Pre-post studies assess clients on the same
variables, and over the same time inter-
vals, before and after they complete treat-
ment. For example, baseline data collected
Method 3:
Pre-post design
Pre-post
studies assess
clients on the
same variables,
and over the
same time
intervals,
before and
after they
complete
treatment
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Simple pre-post designs have some limita-
tions. They do not control for competing ex-
planations, such as something else that hap-
pened during treatment. They also do not
show if a treatment service or system is ef-
fective relative to alternative treatments.
Despite these drawbacks, pre-post evalua-
tions have several strengths. They can de-
termine if treatment objectives are being
achieved, and the type of client who im-
proves most or least. They also can show if
improvement varies with the amount or type
of treatment received. For example, you can
show if those attending treatment consistently
fare better than those with poor attendance.
You also can show if those who attended
specific components of the service did bet-
ter than others. Positive results from a pre-
post study are rewarding for staff and can
satisfy accountability requirements of some
funding agencies. Positive results from pre-
post studies also can lend support for getting
the resources to conduct more rigorous
randomised controlled trials. If your results
seem worse than those reported for similar
clients in other programmes, some action to
improve your services may be needed. If,
on the other hand, the results seem better
than expected, a rigorous evaluation may be
desirable to be sure your programme can
take the credit for these positive outcomes.
The last case report located at the end of this
workbook (by Auriacombe and colleagues)
provides an example of pre-post design. In
this evaluation, clients receiving opiate-sub-
stitute treatment were followed over time.
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Other methodological
issues in outcome
evaluation
Beyond choosing the basic design of your evaluation, there are other methodological details
to be decided. Workbooks 1 and 2 provide valuable general information in this area; be sure
to review them with this workbook. The information in this section is specialised for out-
come evaluations and complementary to the more general information provided in the intro-
ductory workbooks. The following issues are discussed:
1 selecting clients for participation
2 sample size
3 timing and frequency of follow-up
4 preparing and tracing clients for follow-up interviews
5 conduct of follow-up interviews
6 selection and training of interviewers
of cases should be recruited from each
service.
Beyond taking a random sample, there are
no stead-fast rules about who to enrol.
However, the procedures used to select
clients should be stated clearly to ensure
individuals who read your evaluation re-
port understand the procedures and po-
tential biases. Attention should be drawn
to clients who were excluded from par-
ticipation, such as clients who don’t have
a telephone, because exclusions can affect
your results.
The selection of clients for participation in
an outcome evaluation should be deter-
mined by objectives of the evaluation. If
you are interested in general programme
effectiveness, random samples of all cli-
ents who enter treatment in a typical time
period should be selected.1  If, on the other
hand, your objectives of evaluation con-
cern particular types of clients (e.g., opi-
ate users), or clients who complete a cer-
tain amount of treatment, then random
samples should be chosen to represent this
subgroup. If there is a desire to compare
one service with another, then similar types
1. Selecting clients for participation
1One could argue that
all clients, as opposed
to a sample of clients,
should be routinely
followed up for
purposes of
accountability. This is
not usually feasible
given the time and
resources required to
do so.
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There are no simple answers to the ques-
tion, “How many clients do I need to study?”
Much depends on the objectives of the study,
the kinds of clients involved and the kinds of
measures used. Case examples from this
workbook report evaluations with as few as
16 participants to greater than 1,000 par-
ticipants. If the aim is to compare outcomes
of two groups of clients (i.e., males or fe-
males; two programs), the number to be stud-
ied depends on the size of difference you want
to detect between the two groups on the
outcome measure. A statistician will be able
to calculate the required sample size if you
provide the following information:
• the relative sizes of the two groups to be
compared
• the expected frequency of the behaviour
in one group
• the magnitude of the difference that you
want to be able to detect, between groups
• the degree of confidence you want to have
in the results
To show you how this process works, con-
sider this example. Imagine that you want to
find out if males in your programme are more
likely to relapse within the first three months
than females. Assume that you will have data
for an equal number of males and females
and that you expect 40% of males to relapse.
Assume further that a difference of 20%
would be of practical significance, and that
you want to be 95% certain that any such
observed differences were not due to chance.
In this case, the statistician will likely advise
you to collect data on about 180 cases (90
males and 90 females). If, however, you think
that a difference of 10% between males and
females is likely to be of interest, the statisti-
cian will advise you to collect data on 600
cases. More cases are required if you want to
detect smaller differences between groups.
More cases are also required if more than two
groups are to be compared or if the groups are
of unequal size.
When planning the number of people to be
studied in an outcome evaluation, allowance
should be made for clients who cannot be
contacted and for whom outcome informa-
tion will be missing. Remember, your final
sample calculations will be based on the num-
ber of clients for whom you have complete
data. You will have to contact more clients in
order to get this many for final calculations.
The percentage of clients “lost” to follow-up
will vary from situation to situation. It will
depend to some extent on the social stability
of clients and the ingenuity of follow-up work-
ers. It would be reasonable to expect that
up to 30% of cases chosen for follow-up
cannot be traced and to, therefore, increase
the sample selected for follow-up by 30%.
McLellan and colleagues (1996) recommend
a 70% follow-up rate as the minimum stan-
dard for outcome evaluation.
2. Sample size
More cases are
required if you
want to detect
smaller
differences
between
groups.
You have three factors to consider here:
• the point in time at which you start count-
ing weeks/months until the follow-up in-
terval (i.e., 4 weeks after intake and as-
sessment vs. 4 weeks after some period
of treatment participation vs. 4 weeks af-
ter the last treatment contact or formal
discharge)
• the duration of the follow-up interval (e.g.,
4 weeks vs. 8 weeks vs. 12 weeks)
• the time period over which PSU and other
outcomes are assessed
3. Timing and frequency of follow-up
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Start Date
In selecting the start date for the follow-up
period, there are several trade-offs to be
made. If you decide to follow-up a random
sample of clients who are enrolled at intake
and/or assessment, you will obtain the largest
sample. Using this method, results can be
generalised to all clients who have participated
in the programme regardless of the level of
service they eventually receive. On the other
hand, most clients who drop-out of treatment
do so early in the treatment process; many
after their first contact. Selecting your sample
this early in the process will mean more effort
to locate people for follow-up, because early
drop-outs will be more difficult to locate.
If you select your follow-up sample from those
who complete a certain period of treatment,
or who have made a certain number of con-
tacts (e.g., three outpatient visits), you will have
a more stable group to re-contact. You will,
however, have missed the opportunity to de-
termine outcome for those with fewer con-
tacts. If you contact only those completing
treatment, and who are formally discharged,
you will probably have a sample heavily bi-
ased toward positive outcome.
Given the above considerations, we recom-
mend that you start the follow-up period at
the first face-to-face contact for client assess-
ment. McLellan and colleagues (1996) refer
to this as the “intent-to-treat” design and rec-
ommend it as a minimum standard for out-
come evaluation.2  With this approach, your
baseline evaluation information must be col-
lected as early as possible in the intake/as-
sessment process. In many programmes, clini-
cal assessment and treatment planning extends
over several contacts. For the period of the
evaluation, routine assessment procedures
may need to be modified in order to get the
pre-treatment evaluation information at the first
contact for assessment.
The relationship between standard programme
intake/assessment procedures and the collec-
tion of the pre-treatment evaluation data re-
quires careful planning. One option is to con-
duct an evaluation interview in addition to
the normal assessment protocol. The interview
may be conducted by an independent evalua-
tor or by other programme staff. The disad-
vantage of this approach is that the client may
be overburdened by two data collection pro-
cedures that ask for similar information in
slightly different ways. An alternative is to blend
the pre-treatment evaluation questions into the
clinical assessment process. This has the ad-
vantage of reducing the burden on clients and
maximising the use of staff resources if inde-
pendent evaluators can not be used.
...we
recommend that
you start the
follow-up period
at the first face-
to-face contact
for client
assessment.
It
iscommended
that you select
at least a six-
month follow-
up interval and
consider the
potential
benefits of at
least one
additional
contact in
another few
months.
Duration of follow-up period
Your second major decision is the duration
of the follow-up interval. Follow-up studies
published in research journals have reported
on information obtained at many different
points in time after treatment engagement.
Some evaluations report on client changes
at the time of discharge or after a certain
period of outpatient contact. Other evalua-
tions have followed a sample of clients for
several years. Most common are reports of
outcomes assessed after a three, six, or 12
month interval. Outcome studies to be re-
ported in scientific journals typically require
a one to two year follow-up period. The case
examples at the end of the workbook dem-
onstrate this variability. Two evaluations used
a 12-month follow-up, whereas the third fol-
lowed participants for five years.
The timing of your follow-up will have a sig-
nificant impact on your results and conclu-
sions. Short-term follow-up studies will show
better results than longer term ones, because
60%-80% of “relapses” occur in the first
three to four months following discharge
(McClellan et al., 1993).
2Many programmes
have a clerical function
incorporated into the
initial stage of
treatment involvement
which collects basic
demographic
information and screens
the client for
programme eligibility.
It is very difficult to
collect baseline
evaluation data during
such a contact with the
programme. Thus, the
“intention-to-treat”
design often means that
clients are selected for
evaluation at the point
of their first clinical
encounter for
assessment and/or
treatment.
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It is recommended that you select at least a
six-month follow-up interval and consider the
potential benefits of at least one additional
contact in another few months. However,
there are no hard and fast rules that must be
followed, other than that your follow-up pe-
riods and intervals should be consistent with
the objectives of your evaluation.
...it is
recommended
that you select a
90-day period for
your outcome
measures.
Clients selected for evaluation should be asked
to sign a written consent form that explains
the purpose and methods of the follow-up
procedures. A sample form is shown in Work-
book 1, Appendix 2. The consent form should
indicate the reason you are evaluating clients,
the (random) process of selection, assurances
of confidentiality, the timing of the follow-up
and the types of questions to be asked. It also
should indicate that the client has the right to
decline to participate and that their decision
will not influence current or future participa-
tion in treatment. The form records the client’s
name, address and telephone number and asks
for details of other people who may be con-
tacted to assist in locating the client. It is im-
portant to know if follow-up workers can, if
necessary, identify themselves to others who
may respond to the follow-up contact. In out-
4. Preparing and tracing clients for
follow-up interviews
come evaluations, it is common practice to ask
all clients to complete the consent form at in-
take and then take a random sample of those
who agree.
For additional information and advice about
preparing and using consent form, review
Workbook 2 Step 1A, entitled “Manage
Ethical Concerns.”
Your consent form should accommodate the
special circumstances of young clients whose
right to consent to treatment and evaluation
may need to be endorsed by parents or guard-
ians. The legal requirement to obtain consent
from parents or guardians will vary across ju-
risdictions: Check with your local authorities
and/or an ethics board to determine the best
way to proceed in your setting.
The consent
form should
indicate the
reason you are
evaluating
clients, the
(random)
process of
selection,
assurances of
confidentiality,
the timing of the
follow-up and
the types of
questions to be
asked.
Time period for measures
Your third major decision concerns the time
period over which outcomes will be as-
sessed. For example, even though you may
have decided that your follow-up period will
be six months in duration, you still need to
decide the time period over which clients will
be asked to recall their PSU and its conse-
quences. The same time period must be cho-
sen for both the pre-treatment and post-
treatment assessments.
There are trade-offs for any time period you
choose. A client’s PSU in the 30 days prior
to starting treatment may not be representa-
tive of longer term PSU. Thus, comparison of
the 30-day pre-treatment period and a 30-
day post-treatment period may not yield a
reliable and meaningful difference. On the other
hand, if the time period is too long (e.g., 4-6
months), clients may not be able to recall im-
portant information accurately (e.g., frequency
and quantity of PSU; use of health and cor-
rectional services).
Based on these concerns, it is recommended
that you select a 90-day period for your out-
come measures. This time period will need
to be stated clearly to clients and reflected in
your questionnaires during pre-treatment and
post-treatment assessments.
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Many follow-up studies of clients of PSU
services use telephone interviews. There is a
general consensus among evaluators that
telephone interviews can provide valid out-
come data when properly conducted (IOM,
1990). They are a good option for collecting
follow-up in settings where most clients have
telephones. However, they are inappropri-
ate in situations where few clients have
phones, or where phone calls to clients’
homes may violate their rights to privacy.
If telephone interviews cannot be used,
your next best option is to interview cli-
ents on the premises. Arrangements
other than this pose logistical difficulties,
for example, finding suitable places to
conduct interviews without compro-
mising client confidentiality or posing
risks to interviewers. Interviewers should
not go to clients’ homes or other street
addresses except in pairs or with clear
backup support. Otherwise, they may
place themselves at risk. These are not
trivial concerns and the safety of follow-
up workers engaged in face-to-face fol-
low-up should be given careful consid-
eration.
The process of locating former clients for
follow-up can be time consuming and frus-
trating for follow-up workers. This is espe-
cially the case for socially unstable clients and
those who may have relapsed. Interviewers
must be tolerant and flexible. Whether face-
to-face or telephone interviews are planned,
a pre-determined schedule of contact at-
tempts must be followed (e.g., five telephone
calls at varying times of day).
5. The conduct of follow-up interviews
6. Selection and training of interviewers
An important standard for outcome evalua-
tion is that all client interviews and data col-
lection be undertaken by people not associ-
ated with the provision of the intervention.
This is the case for both pre-treatment and
follow-up interviews, although practical and
resource constraints may make it difficult
during the pre-treatment assessment. Re-
source constraints may require that
programme staff assist in the collection of
follow-up information. However, they should
not do so for clients they have treated. This
is important in order to avoid clients “faking
good” at follow-up to the clinical staff who
have treated them.
All data collectors should be trained thor-
oughly before starting work with clients. Re-
view Workbook 2 Step 1C, entitled “De-
velop a Data Management Plan,” for more
information about how to do this.
If your follow-up interviews are to be con-
ducted by telephone, the interviewers must
have a professional manner and clear voices
over the phone. If face-to-face interviews are
used, interviewers should be selected and
trained such that clients feel they can talk
freely. For example, if you are planning face-
to-face interviews and the people to be in-
terviewed are young adults with unconven-
All data
collectors
should be
trained
thoroughly
before starting
work with
clients.
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tional lifestyles, try to engage young interview-
ers who have flexible time schedules and who
feel comfortable in casual clothes and con-
versation. Similarly, a face-to-face follow-up
of adults or elderly persons would best be
done by older, more conventional individu-
als. The gender of the interviewer may also
be important, especially if your programme
has objectives specific to female or male is-
sues.
The language in which the follow-up inter-
views is conducted is of obvious concern.
This may be difficult to accommodate in all
cases, especially if your programme has a
multicultural clientele. Careful attention must
be given to the use of outcome measures
validated in one culture and developed in
particular language, and then translated into
another language. Such cross-cultural appli-
cation may significantly influence the reliabil-
ity and validity of the measure.
Interviewers should be familiar with the in-
terview schedule and objectives of the evalu-
ation. They should practice before they start
interviewing. Interviewers should be trained
to write down responses without translation
or comment. Tape recorders may be used
but these are not always reliable, and tran-
scription can be time consuming. It is impor-
tant that interviewers be well supervised to
ensure they stay within the agreed evaluation
protocol and act professionally.
Whether you are using face-to-face or tele-
phone interviews, an important issue in the
selection and training of interviewers is the
extent to which they are allowed to address
clinical issues that may arise. It is recom-
mended that a written protocol be developed
for interviewers to guide their response to
requests for additional treatment or more
serious emergencies such as expressed sui-
cidal ideation. While clinical training and ex-
perience are usually not required of follow-
up workers, they must be capable of
responding professionally and ethically to a
range of situations that may present them-
selves.
Some programmes have trained former cli-
ents or other volunteers to locate clients and
conduct the follow-up interviews. This may
be an option for programmes with limited
resources for outcome evaluation. In these
cases, particular attention should be given to
training and to monitoring data collection..
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Outcome measures can be selected
from three broad domains:
• reduction of PSU
• improvement in personal and
social function
• reduction in public health and
safety risks
Choosing your
outcome measures
A wide range of potential outcome measures
in each of these domains may be relevant for
the evaluation of your treatment service or
system. Your choice of outcome measures is
critical to the success of your evaluation. The
decisions you make are closely tied to deci-
sions you will have to make regarding data
collection procedures. For example, some
measures will be appropriate for self-comple-
tion, others by telephone and still others may
require a face-to-face interview with particu-
lar groups of clients. Most importantly, your
choice of measures must be guided by the
objectives that your treatment service or sys-
tem is trying to achieve.
The table below identifies many possible out-
come measures within each of these areas:
Domain: PSU
• Workbook 1, Appendix 2 includes a brief
format for measuring quantity/frequency
of PSU
• Timeline Follow-back Method (Sobell
and Sobell, 1992)
• Alcohol and Drug Use Subscales of the
Addiction Severity Index (McLellan et al.,
1988)
• Quantity/Frequency Measures from Di-
rectory of Outcome Measures (Addic-
tion Research Foundation)
Domain: personal and social functioning
• Short Alcohol Dependence Data
(Raistrick et al., 1983)
• Drug Abuse Screening Test (Skinner,
1982)
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• WHO - CIDI (Witchen, 1994)
• Symptom Checklist-90 (Derogatis,
1977)
• Beck Depression Inventory (Beck et
al., 1961)
• the follow-up data collection strategy (i.e.,
telephone versus face-to-face interviews)
• the resources you have available for data
collection, analysis and preparation of reports
In addition to your outcome measures, you
also need measures that help you explain
or predict outcome for certain groups of
clients. For example, PSU is an outcome
measure; while the number of days in treat-
ment is a predictor variable.1  Information
on any given client?s participation in treat-
ment needs to be linked with his/her out-
comes. Demographic characteristics of cli-
ents such as gender, age, and
socio-economic status are often used as
predictor variables. Other predictor vari-
ables could include:
• severity of dependence
• extent of family and social supports
• psychiatric symptoms, in particular the
presence of anti-social personality diagnosis
These predictor variables are measured by
some of the questionnaires listed in the table
above.
Domain: Public Health and safety risks
What information source should you use?
You will have to decide whether to collect all
of your outcome information from one
source (usually the client), or from more than
one source. Having additional information to
back-up clients’ self-reports is recommen-
ded (McLellan et al., 1996) (e.g., breathaly-
ser; urine screening tests, and/or collateral
...ethical
considerations
prevent collecting
data from third
parties (e.g.,
family members)
without clear,
written permission
from clients
themselves.
reports). This may not be practical in all situ-
ations or if limited resources are available for
evaluation.
Do PS users tell the truth? Overall, research
indicates that self-reports of PSU, criminal
and other behaviours are reasonably reli-
1Scientific jargon
refers to these as
dependent variables
(your outcome) and
independent variables
(your predictors).
• Perceived Social Support (Procidano
and Heller, 1983)
• Social/Family Subscale of the ASI
(McLellan et al., 1988)
• Workbook 1, Appendix 2 includes a brief
format for measuring HIV-risk
behaviours, and health, social, and cor-
rectional services
• Legal Sub-scale of the ASI (McLellan et
al., 1988)
These measures are presented as examples
only. You must decide on their appropria-
teness and availability for your clients and
your culture. In making your selection of out-
come measures, you should consider:
• the objectives of your treatment service
• the client population you serve
• the time you are prepared to invest in your
assessment process for the collection of
data
• the potential use of a computer to assist
in collection of the information (i.e., self-
administered questions)
• the time period over which you wish to
have clients report PSU
• established reliability and validity data for
your culture
• cost to use the instrument if not in public
domain
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able and valid under certain conditions
(Sobell et al., 1992). PS users are more likely
to give accurate answers when:
• they are sober and PS free at the time of
the interview
• confidentiality can be assured and there
are no consequences for reporting PSU
or illegal behaviours
• the interviewer is skilled and non-judge-
mental and there is good rapport between
the interviewer and the respondent
• questions are clear, direct and easily un-
derstood by the respondent
There is additional evidence that PS users are
more accurate when they are aware that their
answers will be verified against third party re-
ports or official records. Such verification is not
always possible, but if family members can be
interviewed or police records checked, clients
will have less reason to deny their actions to you.
Not every client will tell “the whole truth and
nothing but the truth” about every aspect of
their lives in treatment outcome studies. Some
will be motivated to under- or over-report
certain behaviours and many will not remem-
ber everything they did, or everything that
happened to them. However, if the condi-
tions for the interview are right, few respon-
dents are likely to present distorted accounts
of their lives and behaviours over a given fol-
low-up period.
Face-to-face interviews present opportu-
nities to observe former clients and these
observations may give clues about their lives
and situations. Interviewers can be trained
to rate clients with respect to their levels of
intoxication, appearance and mood and signs
of PSU, for example, smell of alcohol, pres-
ence of bottles or syringes and other para-
phernalia, or needle marks on the arms.
Family members and friends may know about
the lives and behaviours of former clients and
be willing to report these to evaluators under
certain conditions. However, ethical consid-
erations prevent collecting data from third
parties(e.g., family members) without clear,
written permission from clients themselves.
When this permission has been obtained,
third parties approached for an interview
should be told why the information is needed
and what the consequences will be for the
client. Reports from third parties will be most
reliable under the same conditions as those
identified for client interviews.
A serious limitation to third party interviews
is that respondents are often unaware of the
behaviours of individual clients. PSU may
take place in private or away from family
members and friends. Clients may not always
tell others what they have been doing. Fami-
lies and friends may have observed clients in
various states of intoxication, however, and
be willing to report this to a follow-up worker.
Records kept by police, hospitals, employ-
ers, welfare workers and other agencies may
indicate contacts with former clients. These
records may be accessible if clients have
given written permission. The value of these
records for treatment outcome studies var-
ies with the type of clients treated. For cli-
ents who typically have contacts with crimi-
nal justice, health or social agencies records
kept by these agencies may show significant
changes following treatment. If clients typi-
cally have few contacts with these agencies,
searches of records may turn up little value.
The value of records for outcome measure-
ment depends on their completeness and
accessibility. When records are not comput-
erised, or stored alphabetically, a great deal
of effort may be needed to abstract relevant
information on individual cases.
Recent alcohol use can be detected with a
breathalyser or through urine and blood tests.
Less recent use of certain psychoactive sub-
stances can be detected in urine, blood, and
hair samples. Tests of these samples require
supplies and equipment for collection of
specimens. Access is also needed to prop-
erly equipped laboratories. The costs in-
volved may be prohibitive for many
programme evaluations.
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Recently, more attention has been given to
assessing outcomes associated with large
networks of treatment programmes. Sys-
tem-level outcome evaluation can involve
any of the evaluation designs described
above — randomised controlled trial, com-
parison group, or pre-post test. In practi-
cal terms, however, it is difficult to randomly
assign clients to one network of services
versus another. The most practical design
to implement at the system-level is the pre-
post design with the same data collected
from all programmes in the defined network.
Large scale outcome monitoring systems are
now operational in the USA and Canada
(e.g, Harrison et al., 1996; Policy and Ser-
vice Consultation Information and Funded
Services, 1995). Others are being devel-
oped elsewhere. The second case example
located in the back of this workbook (by
Gossop and colleagues) is a good example
of an outcome evaluation at the national
system level.
Practical issues are considerably magnified
with outcome evaluations at the system-level:
• involvement of a wider range of key
groups in the evaluation process and more
difficulty achieving consensus on outcomes
to be measured
• more involvement of funders and/or pay-
ers in developing the evaluation questions.
They may, for example, find it difficult to
formulate specific policy questions that
they would like addressed
• difficulty identifying relevant outcomes
across programmes with widely varying
objectives and client populations (e.g.,
detoxification centres, assessment and
referral centres, treatment programmes
aftercare programmes, youth
programmes, and programmes serving the
elderly, the homeless, or multicultural
populations)
• more difficulty getting system-wide buy-
in to the evaluation process due to fear
that the results will be used to restructure
the system in dramatic ways and cut pro-
grams
• limitations of the pre-post evaluation de-
sign in attributing causality to outcomes
obtained and fearing that the results will
be used inappropriately for policy deci-
sions
• fear among service providers that if out-
comes are being measured in a sample
of agencies the results may not be repre-
sentative of their program
For these reasons, it is recommended that
you consult with an experienced outcome
evaluation researcher before attempting a
project at the system level.
Outcome evaluation at
the system-Level
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Its your turn
Put the information from this workbook to use in your own setting or treatment system.
Complete these exercises below.
Remember to use the information from Workbooks 1 and 2 to help you complete an evalu-
ation plan. Review that information now, if you have not already done so.
Exercise 1
Think about your treatment programme. List five general areas in which you want to know
the effectiveness of your programme.
Example: Is our women’s programme effective?
Exercise 2
For each area that you listed above, choose a series of specific questions to ask:.
Example (from above):
A) Does our women’s programme reduce PSU?
B) Does our women’s programme reduce the severity of depressive symptoms?
C) Among participants, do younger or older women do better?
Now it’s your turn. Follow the same procedure for each of the five areas that you listed in
Exercise 1.
1
2
3
4
5
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Yes   No
Exercise 3
Review the questions that you created in
Exercise 2. Consider which of these ques-
tions are feasible to study, and which are
most important to study in your setting. You
should review Workbook 1, Evaluation Plan-
ning, for additional information about how to
do this. Once you have settled on key ques-
    open-ended items on self-administered questionnaire
    one-on-one interviews
     focus groups
    program documents
    clinical observations
tions, decide how you will measure each of
them.
Review potential outcome measures using the
appendix in this workbook, other resource
manuals, and if possible, consultation with
evaluators in the PSU field. Then:
A. Decide which of these data collection methods you will use:
B) Decide how data will be collected and by whom:
Baseline data  Follow-up worker Follow-up method
blended with clinical assessment  independent evaluator telephone
separate from clinical assessment programme staff face-to-face
but collected by programme staff volunteer mail out
collected by external evaluator flexible depends on flexible depends on
client       client
Example (from above):
Data will be collected using self-administered
questionnaires and corroborating medical chart
data:
a) PSU:
- Questions about frequency, quantity, and
type of PSU over the past eight weeks
- Review of medical records for results of
intake and discharge toxicology screens
b) Depressive symptoms: The Beck Depres-
sion Inventory
c) Age: General demographic questions
All data will be collected by an external evalu-
ator, using face-to-face contact within the clinic
building, and separate chart review.
Now it’s your turn. Follow the same proce-
dure for each of the questions that you listed
in Exercise 2.
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Exercise 4
Using the information provided in this workbook about how to design and conduct an
outcome evaluation, make the following decisions:
Example (from above):
•  Given programme resource limitations, a
pre-post design will be used.
•  All clients checking in for their assess-
ment appointment will be asked by staff
to meet with an external evaluator while
waiting for their appointments. Pre-
treatment data will be collected over a
three month period of time.
•  After agreeing to participate, clients will
be given the questionnaires, and enve-
lopes in which to place their completed
questionnaires before returning them to
the evaluator. Clients will be instructed
to complete the questionnaires before
leaving the clinic that day. The following
statement will appear at the top of the
questionnaire:
“Please help us improve our programme
by answering some questions about your
PSU and related problems. To ensure
• Choose an evaluation design:
- experimental
- comparison group
- pre-post
• Choose a sampling procedure for choosing clients to survey
• Decide the timing of the evaluation
• Develop a procedure for ensuring clients’ confidentiality and promoting their honesty
in answering questions.
your confidentiality, please do not write
your name on this form. When you are
finished, place the form in the envelope
(provided) and seal it closed, then give it
to the evaluator in the waiting area.”
•  ID numbers will be used in place of names
on all questionnaires. A confidential list
will be kept that links these ID numbers
with clients? names and contact informa-
tion. This list will be kept separate from
the data, to further ensure client privacy.
Three months after discharge from the 8-
week programme, the clients will be con-
tacted by the evaluator to schedule a fol-
low-up meeting that is roughly 6 months
post-admission. Clients will return to the
clinic for this confidential follow-up meet-
ing, where they will complete the same
questionnaires and return them to the
evaluator.
Now it’s your turn. Follow the same proce-
dure for your evaluation questions.
Exercise 5
You will need to prepare a consent form that
explains the purpose of your study. Review
Section 1A of Workbook 2, entitled, “Man-
age Ethical Issues,” for more information
about the important topic of participants’
rights in evaluation research. Also review
Workbook 1, Appendix 2 for an example of
an outcome evaluation consent form.
In general, all participants should be asked
permission ahead of time before being en-
rolled in the study. When you do this, your
should explain the purpose, nature, and time
involved in their participation. No person
should be forced or coerced to participate
in the study.
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•  describe the purpose and methods of the study
•  explain what they will need to do if they participate
•  explain that participation is voluntary
The consent form should:
Exercise 6
Run a pilot test of your evaluation mea-
surement and procedures (including your
follow-up interviews) to ensure that every-
thing runs smoothly. Review section 1C of
Now it’s your turn. Using the example in
Appendix A, and the information provided
in Workbook 2, section 1A, write your own
consent form.
Workbook 2 entitled “Conduct a Pilot
Test” for specific information about how
to do this. In general, pilot tests assess
these questions:
•  Do the questions provide useful information?
•  Can the questions be administered properly? For example, is it too long or too
complicated to be filled out properly?
•  Can the information be easily managed by people responsible for compiling the
data?
•  Does other information need to be collected?
Example (from above):
A pilot test will be run during one clinic day:
3 November. During this day, all patients
checking in for an assessment appointment
will be asked to complete the questionnaire.
Afterwards, their responses will be exam-
ined to determine whether they seemed to
understand the questions and were answer-
ing honestly. All persons involved with dis-
tributing the forms and tallying the data will
be interviewed to determine their views on
any improvements that could be made in the
process and/or to the forms. Follow-up con-
tact procedures and interviews also will be
pilot tested.
Now it’s your turn. Write down how you will
pilot test your evaluation study. Don’t forget
to review Workbook 2 first!
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Conclusion and
a practical
recommendation
In this workbook, we have outlined the ba-
sic principles and practices of outcome
evaluation of PSU services and systems.
The goals of this type of evaluation are the
assessment of change within different di-
mensions of the client’s life and demonstrat-
ing that your programme had a role to play
in causing these changes. You have learned
about the design of outcome evaluations —
experimental, comparison group, pre-post
— and how your choice of design affects
the confidence you have in attributing
changes in client’s to their participation in
your program. You also have learned about
other methodological issues important for
all types of outcome evaluation.
A word of advice: trade-offs always have to
be made to the rigour with which you col-
lect and analyse information to answer evalu-
ation questions, and the amount of re-
sources available to you. This is especially
true for outcome evaluations. Your research
goal should be to achieve the best possible
information with the expertise and resources
available in your setting. Be sure to review
your resources carefully before embarking
on an outcome evaluation.
After completing your outcome evaluation, you
want to ensure that your results are put to prac-
tical use. One way is to report your results in
written form (described in Workbook 2, Step
4). It is equally important, however, to explore
what the results mean for your programme.
Do changes need to happen? If so, what is
the best way to accomplish this?
Return to the expected user(s) of the research
with specific recommendations based on your
results. List your recommendations, link them
logically to your results, and suggest a pe-
riod for implementation of changes.
Remember, outcome evaluations provide
important information on the effectiveness of
your programme. It is important to use the
information to improve treatment services.
Through careful examination of your results,
you can develop helpful recommendations for
your programme. In this way, you can take
important steps to create a “healthy culture
for evaluation” within your organisation.
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Sample Consent Form
PLEASE READ THIS CAREFULLY AND RETURN A SIGNED COPY TO YOUR COUNSELLOR. PLEASE
KEEP THE SECOND COPY FOR YOUR OWN RECORDS.
This form deals with your consent to take part in a follow-up study conducted by _______________________.
The purpose of this study is to help evaluate the services provided by the program.
IF YOU ARE 16 YEARS OF AGE OR YOUNGER you may also wish to have your parent(s) or guardian(s)
read this form and provide their written consent. If they have any questions regarding this study they should
feel free to contact the staff of programme at... telephone no... during regular business hours.
In consenting to participate in this study I understand:
1 I will be contacted by mail or telephone in about 6 months by a follow-up worker to arrange a personal
interview;
2 that at the interview I will be asked questions about my psychoactive substance use and other behaviours
during the last six months;
3 that in the event the follow-up worker is unable to reach me at the telephone number or address given
below, he/she may contact the following people to determine my whereabouts upon the condition the he/
she does not reveal any details about my participation in the study or why he/she wishes to contact me;
Name of contact person                             Area Code & Telephone No. Relation
1.
2.
4 that the information given to the follow-up worker will be treated as confidential. It will not be shared with
my assessment worker, any persons at the program, or any other agencies;
5 I will not be identified in any reports and all published reports based on this study will only refer to grouped
data;
6 I reserve the right to decline the interview, or if I agree to the interview, I may refuse to answer specific
questions or terminate the interview at any time.
7 also understand that my participating in the study does not promise any therapeutic benefit. If I decline to
participate in the study or withdraw later, this will not affect the services I receive from the staff of the
program.
I, (signature), (date) hereby consent to take part in the follow-up study as outlined above.
Please print:
Name of client     Address
Name of witness      Date    Signature
PARENT OR GUARDIAN:
My signature, (date) will serve to acknowledge my having read this form and agree that my child/ward may
take part in the follow-up study subject to the conditions described above.
Name of witness      Date    Signature
Appendix 1
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Appendix 2
Outcome measures
Instruments in Appendix 2 are adapted from
a data collection protocol for treatment pro-
cess and outcome monitoring being devel-
oped by the Addiction Research Founda-
tion, Ontario, Canada. Information about the
instruments can be obtained from: Addiction
Research Foundation, 100 Collip Circle,
Suite 200, London, Ontario, Canada, N6G
4X8.
These measures are presented as examples
only. Reliability and validity data are not avail-
able. You must decide on their appropriate-
ness and availability for your clients and your
culture. In addition to considering these in-
struments, a review of the ARF Outcome
Measures Directory (undated) is highly rec-
ommended. This Directory contains many
potentially useful instruments for process
evaluation and discusses reliability, validity,
and practical issues in administration.
Several ARF measures also were adapted
for an outcome-monitoring project in Illinois,
U.S.A. For more information about these
measures, contact Dr. Michael Dennis, Light-
house Institute, Chestnut Health Systems,
702 West Chestnut, Bloomington, IL, 61701,
U.S.A.
Psychoactive substance use
Substance
Used in past
12 months
(1= Yes / 2= No)
Number of days
used in past 90
(Days)
Average quantity
per day of use in
past 90 days*
Use currently a
problem?
(1= Yes / 2 = No)
* It may be difficult to quantify the exact amount for certain substances. Indirect estimates can be made from the number of times per day a substance is injected, inhaled,
snorted, or smoked.
Alcohol (beer, liquor, wine)
Cocaine/ crack/ coke
Amphetamines/ other stimulants
Cannabis (hash, weed, grass, pot, marijuana)
Benzodiazepines
Barbiturates
Heroin/ opium
Prescription opioids
Over-the-counter codeine preparations
Hallucinogens
Glue/ other inhalants
Tobacco
Other psychoactive substances
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i) During the past 90 days, on how many days did you inject
any kind of psychoactive substance?
ii) Have you ever shared a needle, syringe, cooker/spoon or
cotton/filter with anyone at any time in your life?
If Yes, during the past 90 days, on how many days did you share
a needle, syringe, cooker/spoon or cotton/filter with anyone?
    During the past 90 days, with how many people have you
shared?
Risk behaviour
1 Thinking about your use of psychoactive substances, have you:
Never injected Injected prior to one year ago
Injected in the last 12 months Unknown
If ever injected, answer the following questions:
Health and correctional service utilisation
1 Thinking about physical health problems, during the past 90 days, how many:
• times have you had to go to the emergency room times
• nights total did you spend in the hospital nights
• times did you have an outpatient surgical procedure times
• times did you see a doctor in an office or outpatient clinic times
2 a) Thinking about mental health problems, during the past 90 days, how many:
• times have you had to go to the emergency room times
• nights total did you spend in the hospital nights
• times did you see a doctor in an office or outpatient clinic times
days
days
people
2 How often do you use condoms with your sexual partner or partners?
Never Sometimes Always
During the past 90 days, how many times have you had
unprotected sex?
times
3 During the past 90 days, on how many days have you driven
a motor vehicle or used a machine at the workplace while
under the influence of alcohol or other psychoactive sub-
stances?
days
Yes No No response
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b)Are you currently in any type of treatment or counselling for mental or emotional
problems?
3 Over the last 90 days, how many days have you received alcohol or substance use
treatment at the following places?
• a hospital overnight for withdrawal or related problems days
• an inpatient substance use treatment facility (3 -90 days) days
• a long-term (3 to 12 months) residential program or
therapeutic community for substance use disorder treatment days
• a methadone or other opioid treatment program days
• an assessment or outpatient substance use treatment facility sessions
• a mental health centre or facility as an outpatient sessions
• an employee assistance program sessions
• a family and/or marital counselling service sessions
• an emergency room days
• a private doctor’s office visits
• a prison or jail days
• some other place (please describe __________________ ) days
Yes No No response
4 a) How many self-help meetings, (e.g., AA, NA, ACOA)
have you attended for your substance use problem in the past
90 days?
b) How many self-help meetings have you attended for is-
sues other than substance use problems in the past 90 days?
meetings
meetings
5 a) During the past 90 days, how many days have you been on probation or parole or
been in jail or custody?
• Probation days
• Parole days
• Jail/prison/closed custody days
• Open custody days
b) During the past 90 days, how many times have you been
charged for breaking the law (please do not count minor traffic
violations)?
times
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Were you charged with:
• driving while impaired
• drunkenness or other liquor law violation
• possession, distribution, or sale of illegal substances
• sexual assault
• theft (including B&E, theft over and theft under)
• violence against family or others
• major crime
• Other (please describe __________________________  )
Please
check if
Yes
# of charges
in the last
90 days
33Workbook 7  •  Outcome Evaluations
WHO/MSD/MSB 00.2h
Comments about
case examples
The three following case examples demon-
strate different types of outcome evaluations.
Each of the evaluations were based on dif-
ferent questions about treatment outcome,
and each used different evaluation methods.
The first case example, written by Formigioni
and Marques, presents a comparison be-
tween group and individual cognitive-
behavioural treatment for PS dependence in
Brazil. Evaluators used a randomised con-
trolled trial design, a rigorous and technically-
challenging type of outcome evaluation. Par-
ticipants were assessed at their initial intakes,
and one year later. Results indicated no sig-
nificant differences between groups after ini-
tial levels of outcome variables were taken
into account. Of note, evaluators encouraged
all participants to complete follow-up inter-
views, regardless of whether they finished
treatment. They also statistically controlled
for initial levels of outcome variables using
an ANCOVA technique. Their evaluation
decisions, while scientifically rigorous, prob-
ably contributed to nonsignificant results. This
case underscores the point that decisions
about data collection and analysis can affect
results.
The second case example, written by Gossop
and colleagues, presents a national level out-
come evaluation of four types of PSU treat-
ment in the United Kingdom. The evaluation
is large-scale: a total of 54 treatment agen-
cies were selected for inclusion in the evalu-
ation, and over 1,000 clients were recruited
for participation. Evaluators chose a natu-
ralistic design: participants were not randomly
assigned to treatment groups, but rather, as-
sessed in the context of care that they were
already receiving. While naturalistic evalua-
tion designs are considered by many to pro-
vide less reliable information about treatment
outcome than randomised controlled trials,
the authors present a compelling argument
for their choice of this design strategy.
The third and final case example, written by
Auriacombe and colleagues, describes an
outcome evaluation of the use of
buprenorphine for people with opiate depen-
dence. Evaluators followed sixteen partici-
pants over a one-year period, using a pre-
post design. This evaluation strategy has
some limitations, such as that it does not con-
trol for competing explanations in participants’
improvement. Nonetheless, evaluators were
able to demonstrate general safety of and
adherence to treatment. Results were used
to convince legislators to change national
regulations regarding the use of this opiate
substitute medication.
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Case example of
outcome evaluation
Comparison between individual and
group settings in the cognitive-
behavioral therapy for individuals
with alcohol and/or drug
dependence
by
Maria Lucia O. S. Formigoni
Sc.D., Professor at the Department of Psychobiology (Federal University of São Paulo),
UDED (Drug dependence Unit) and project coordinator, Researcher from CNPq (Conselho
Nacional de Pesquisa).
Botucatu 862 / 1o andar
04023-062 - São Paulo - SP - Brazil
E-mail: mlformig@psicobio.epm.br
and
Ana Cecilia R.P. Marques
Sc.D., researcher from Association of Incentive to Psychopharmacology (AFIP). Financial
support from AFIP, a Brazilian non-profit institution.
Who was asking the
question(s) and why
did they want this
information?
The lack of public resources to address
health and social problems is a very seri-
ous issue in Brazil. Therefore, it is very
important to find the most cost-effective
solutions for health and social problems,
including Addiction treatment. In Brazil,
there is little information available about the
effectiveness and cost-effectiveness of
Addiction treatment. Traditionally, people
who are drug and alcohol dependent are
treated either by psychiatrists at private
offices/clinics or at public mental health
hospitals. Most are based on the Minne-
sota model, including 28-day to three-
month inpatient care, and participation in
AA meetings. The less severe cases are
usually referred to outpatient intervention,
available at private offices (individual set-
ting) or public health units (group setting).
The authors alone are
responsible for the
views expressed in
this case example.
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Since 1989, brief interventions have been
compared with more traditional models to
treat alcohol/drug dependence in Brazil.
The Brief Intervention Model proposed in
Canada by Sanchez-Craig (1984, 1990)
and Sanchez-Craig et al (1984, 1987,
1989) was adapted to Brazilian conditions
under the supervision of those authors at
the turn of this decade (1989-1991). Af-
ter that experience, further adaptations
were performed in order to fit the needs
of Brazilian clients (Formigoni et al., 1992,
Formigoni & Neumann, 1993, Sanchez-
Craig et al. 1991). After some changes to
the treatment model (e.g., increased num-
ber of sessions and more comprehensive
approach) this technique is now closer to
what can be called a brief cognitive-
behavioural therapy.
In order to estimate the effectiveness of the
adapted treatment model, the co-ordinator
and the staff of UDED (Drug Dependence
Unit — Department of Psychobiology —
Federal University of São Paulo — Brazil)
decided to perform an outcome evaluation.
They decided to undertake a randomised
control group trial to evaluate the effective-
ness of the method currently used to treat
substance abusers and dependants. The
most important factor to be studied was the
influence of setting (individual or group ses-
sions) on outcome. Also of interest were
the characteristics of the clients who re-
sponded to this kind of treatment with a
good attendance record. Should the group
setting outcome turn out to be similar to the
outcome in individual settings, the former
would be selected as a “standard”, since
the cost per client is significantly lower. In-
dividual setting would only be available to
“special” cases.
The main questions to be answered with infor-
mation from the evaluation process were:
• How effective was the cognitive-
behavioural therapy utilised for alcohol
and/or drug dependent clients?
• Did clients who completed treatment de-
crease their alcohol and drug use signifi-
cantly one year after assessment?
• Did clients who dropped out during treat-
ment differ from those who completed
treatment on their initial characteristics
(drug abused, dependence level, associ-
ated problems)?
• Was outcome better for those who com-
pleted treatment than for those who
dropped out?
• Was there a difference between individual
and group settings on client attendance at
treatment or the outcome?
• Did the kind of substance abused influ-
ence the attendance rate or the outcome?
What resources were
needed to collect and
interpret the
information?
UDED staff developed the evaluation pro-
cess, after having received the training to
do so. The data were inputted by a secre-
tary on a DbaseIII-Plus datafile, as they
were being collected (at assessment, dur-
ing treatment and at follow-up interviews).
The UDED co-ordinator and a post-gradu-
ate student spent about 500 hours extract-
ing data, performing all statistical analyses
and writing reports in a personal computer.
The UDED team (2 psychiatrists, 2 psycholo-
gists and 1 secretary) was supported by the
Association of Incentive to Psychopharma-
cology (AFIP) a NGO non-profit
organisation.
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How were the data
collected?
Design of outcome evaluation
The staff chose a quantitative approach — a
randomised control group design — to per-
form the outcome evaluation.
Sample selection: The study included cli-
ents admitted to treatment between 1993 and
1994. Given the characteristics of the pro-
gram, only clients with no serious physical or
psychiatric disorders were admitted, pro-
vided they met DSMIII-R criteria (APA,
1987) for alcohol and/or drug abuse or de-
pendence, had at least 4 years of formal edu-
cation, had a fixed address and agreed to
participate in the follow-up evaluation.
Sample size: Previous data showed that
about 30% of alcohol/drug dependent indi-
viduals admitted to the individual setting treat-
ment were considered “successful” one year
after assessment. To assess the influence of
setting (group vs. individual), we established
that a difference of 15% between settings
would be considered of practical significance.
We also wanted to be 95% certain that dif-
ferences observed were not due to chance
(alpha error rate = 0.05), and that in the case
where groups being considered were simi-
lar, the possibility of this happening by chance
would not be over 20% (beta error rate of
0.20). With these data, we calculated the
sample size utilising the Process Analysis
module of the statistical software
CSS:Statistica (Statsoft, 1991). The mini-
mum “N” calculated was 58 clients per
group. It is important to consider this as the
expected sample size for each group at fol-
low-up. Considering a probable 30% drop-
out rate, it was calculated that the minimums
of 75 clients were required per group. The
data were collected by each professional in
charge of assessment, treatment and follow-
up of clients, and recorded in standardised
forms.
General procedure: After the initial assess-
ment to determine whether clients would be
admitted or referred elsewhere, clients were
randomly assigned to one of the two setting
modalities (individual vs. group) by a previ-
ous lot. A follow-up evaluation was per-
formed approximately one year after assess-
ment.
The initial assessment: The initial assess-
ment data were collected by one of the two
psychiatrists trained to do so. The interview
included a comprehensive alcohol and drug
use history of the client, client’s social and
demographic characteristics, drug depen-
dence diagnosis according to DSMIIIR cri-
teria (APA, 1987) plus a clinical and psy-
chological evaluation. The drinking history for
the past 90 days, and also a lifetime alcohol
and other drugs history were obtained by
means of a standardised inventory, adapted
from Martin et al. 1991. The drug use was
categorised according to an index of drug
use severity (Wilkinson & LeBreton, 1986).
The SADD (Short Alcohol Dependence
Data - Raistrick et al., 1983) was used to
evaluate adverse consequences of alcohol
use. A standardised medical examination
was done including laboratory tests (GGT,
ALT, AST and MCV). After the medical
interview, clients underwent psychological
testing (Rainho, 1962, Weschler, 1987,
Moraes et al., 1992) to ensure their ad-
equate cognitive capability, since this is
required by the technique. The tests were
applied by graduate students of psychol-
ogy under the supervision of a specialised
psychologist. All clients with severe medi-
cal or psychiatric problems who needed
inpatient care were referred to other
specialised services.
During the interview, clients were informed
about the main objectives of treatment, that
their data would be included in a Research
protocol, and their confidentiality would be
preserved. They signed a consent form
authorising the staff to use their data and
agreed to provide blood and urine samples
for laboratory tests (hepatic enzymes and
drugs/HIV detection). They also provided a
name of a collateral person to be contacted
at follow-up.
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Treatment procedures: The treatment was
developed in 17 sessions, over a six-month
period. One session per week was held in
the first three months. The sessions in the
fourth and fifth months were held every two
weeks and in the sixth month, one session
was held. The first treatment session was in
an individual setting for both groups. It in-
cluded a review of assessment data, a dis-
cussion about laboratory results and orien-
tation about changes that could be expected
if alcohol/drug use were to be reduced. The
clients’ concepts about their problems related
to substance abuse were discussed, followed
by the therapist presentation of key concepts
and proposals. This included the concept that
excessive drug/alcohol use is considered a
learned habit that people could change with
some effort. A therapeutic contract was then
presented, including some rules about atten-
dance at therapy sessions and homework
assignments. After this, clients signed a con-
sent to participate in which they authorised
the use of their data having been assured that
confidentiality would be preserved.
The therapist pointed out the need for absti-
nence from alcohol and drugs as the initial
goal for the first three months of treatment.
For alcohol dependent clients, the possibil-
ity of moderation as a long-term goal was
discussed when clients expressed desire for
reduction and not for total abstinence. This
possibility was only to be considered if cli-
ents presented normal laboratory tests and
no physical/psychological alterations at clini-
cal examination.
After this initial session, half of the sample
was randomly assigned to the individual set-
ting and the other half to the group setting.
The groups remained open during the first
month, receiving up to 10 clients. After this
period of time, the group was closed with
any number of bigger than three.
The treatment was developed in 17 sessions
over a six-month period, divided into two
phases: acquisition and maintenance. The first
eight sessions were considered the acquisi-
tion period, in which the clients should ac-
quire skills to recognise their problems and
to develop strategies to cope with them. It
included procedures such as: identification of
risk situations (using the Inventory of Drink-
ing Situations - Annis & Graham -1987) and
the roles attributed to drug use; self-moni-
toring of alcohol/drug use utilising a self-moni-
toring card; identification of possible means
of support and strategies for reaching the
goal; evaluation of the use and effectiveness
of strategies, etc.
After clients were trained to develop effective
ways of coping with risk situations, they en-
tered the “maintenance phase”. The purpose
of this phase was to ensure the maintenance of
improvements accomplished by clients and to
encourage them to continue using strategies
developed in the previous phase.
Treatment attendance data: The atten-
dance at treatment sessions was recorded
on special client forms. At each session, the
therapist filled out a form in which the fol-
lowing data were considered: level of alco-
hol/drug consumption; if the goal was being
reached; work/school, family, leisure, physi-
cal, psychological and legal situations.
Follow-up data: The follow-up evaluation
was done by the same professional who had
interviewed him/her at assessment but was
not involved in treatment. Clients were in-
vited to come to a face-to-face interview simi-
lar to that performed at initial assessment (in-
cluding laboratory tests). If the client refused
to come, at least a phone interview was tried.
During the follow-up interview, clients were
also asked to make a self-evaluation about
their current alcohol/drug problems, in which
they considered their current status in rela-
tion to assessment, classifying themselves as
“successful”, “improved” or “unimproved/
worse”. They were also asked to evaluate the
treatment’s contribution to their improvement.
A collateral recommended by the client was
also interviewed by an independent person,
in order to give objective data about the
client’s alcohol/drug consumption and
problems.
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How were the data
analyzed?
Data base: The data were transferred to a
statistical package (CSS/Statistical) after a
careful check to prevent missing or out of
range data inclusion.
Statistical methods: The comparisons be-
tween the two different setting groups were
made by the student’s “t” test for independent
samples, when variables taken into account
were measured at least in an interval scale. If
the substance being abused was included in the
analysis, a two-way ANOVA (Analysis of Vari-
ance) was made, followed by post-hoc tests
(Duncan’s multiple range test). When differences
between groups were detected at assessment,
the initial values were considered covariate vari-
ables in the follow-up comparison.
The Mann Whitney U-test was utilised when
variables were measured at an ordinal level
or if there was not a normal distribution of
values. Comparisons of frequencies between
groups were made using the Chi-square (X2)
test. Comparisons between pre- and post-
treatment data were made by the t-test for
dependent samples (interval measurements),
Wilcoxon matched pairs test (ordinal mea-
surements), MacNemar’s chi-square test or
Cochran q test (nominal measurements). The
same kind of procedure was done to com-
pare treatment attenders and non-attenders.
In all cases, the level of significance consid-
ered was 5%.
Spearman Rank Order coefficients were
calculated to explore relationships between
assessment and outcome variables in order
to look for predictors of success and com-
pliance to treatment.
What did they find out?
Before comparing settings (individual vs.
group) at follow-up, samples were compared
on their assessment data and treatment at-
tendance. Data collected at follow-up were
then compared with those collected at as-
sessment (intra-group analysis).
Client characteristics: The study included
155 clients admitted to treatment between
1993 and 1994 and evaluated at least one
year afterwards. Half of them (77) were
treated in an individual setting and the others
(78) in a group setting. The two samples were
similar in relation to all characteristics at the
initial assessment.
Table 1 shows the main social-demographic
characteristics of both samples, divided into
two groups, according to main substance
abused: “alcohol” (only alcohol abuse or
dependence) or “drugs” (other drug depen-
dence including alcohol or not). Most clients
were men, employed, with 10 years of for-
mal education (varying from 4 to 24 years)
and had monthly incomes over US$500.
Drug dependants differed from alcohol cli-
ents in age (younger) and marital status (more
were single).
Table 2 presents data on social relationships,
living arrangement, family and personal sub-
stance abuse and a history of psychiatric dis-
orders. Most clients lived with family, had a
positive family history of alcohol and/or drug
abuse, and had previously participated in
other treatments. About 30% presented
some kind of psychiatric disorders or had
participated in psychiatric treatment in the
past. Only three clients from the alcohol group
(individual setting) scored below average in
the psychological tests. All others presented
normal scores.
Table 3 shows dependence levels diagnosed
at initial assessment. No differences between
settings or drug groups were detected. Pro-
portions of clients with psychological and
physical disorders, according to physician’s
clinical diagnosis, are also presented, as are
the mean values (± standard deviations) of
laboratory tests. It can be observed that
many alcohol dependent clients showed al-
tered MCV, GGT, GTO and GTP. Drug
dependants presented lower percentage of
altered tests and equal or lower mean levels.
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TABLE 1: Sociodemographic characteristics of the sample.
Percentage of clients.
Setting INDIVIDUAL GROUP TOTAL
Substance abused Alcohol Drugs Alcohol Drugs Alcohol Drugs
Number of clients 31 46 36 42 67 88
Age (mean ± sd) 40 ± 8 26 ± 8¸ 41 ± 8 24 ± 7¸ 41 ± 8 25 ± 8¸
Sex
male 77.4 84.8 94.4 90.5 94.4 90.5
female 22.6 15.2 5.5 9.5 5.6 9.52
Marital status
single 19.4 63.0˚ 5.5 69.0˚ 19.4 65.9˚
married 61.2 30.5 19.5 11.9 59.7 21.5
separated 19.4 6.5 58.3 19.1 20.9 12.5
Employment status
employed 64.5 60.8 72.2 66.7 68.6 63.6
unemployed 25.8 26.1 16.6 28.5 20.8 27.3
retired 0 0 5.6 0 2.9 0
student or other 9.7 13.1 5.6 4.8 7.4 9.1
Education (years)
up to 8 35.5 41.3 47.2 45.2 41.8 43.2
9 - 11 22.6 43.5 16.6 33.4 19.4 38.6
college 41.9 15.2 36.2 21.4 38.8 18.2
Income (US$)
100 - 499 25.8 39.1 27.8 21.4 26.9 30.7
500 - 999 25.8 13.0 19.4 21.4 22.4 17.0
1000 or + 48.4 47.9 52.8 57.2 50.7 52.3
No differences between settings were detected.
Comparisons between alcohol and drugs in the same setting or total sample:
˚ p< 0.05 comparison by X2
¸ p< 0.05 comparison by Student?s t test for independent samples
Treatment attendance data: Clients were
considered “treatment attenders” if they
showed up for at least eight sessions (which
would correspond to acquisition phase). Cli-
ents were considered to be “complete
attenders” if they attended on a regular basis
until the last session (17th session) and “par-
tial attenders” if they completed at least the
acquisition period (first eight sessions) and
dropped out during the maintenance phase.
Table 4 shows the main attendance data for
both groups, divided according to drug
abused. Alcohol dependent clients treated in
group setting tended to have higher atten-
dance than those treated individually (p<
0.06, Fischer exact p, one-tailed) and also a
significantly higher attendance than drug
dependants treated in group (X2= 5.9
p<0.05). However, regarding drug
dependants, no significant differences in at-
tendance rates were observed between the
settings. The average number of sessions was
similar (7 ± 8) for both settings, but it was
observed that alcohol clients attended sig-
nificantly more sessions than drug
dependants. This difference was particularly
clear in the group setting. Considering only
the clients treated in group, if complete
attenders are compared with the others
(dropouts at acquisition + partial attenders),
a significant difference in attendance is de-
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tected between alcohol and drug dependants
(X2 = 4.7 p< 0.03), showing the low com-
plete attendance of drug clients in the group
setting (19%).
All subgroups presented similar referral and
dropout rates. About 50% of the clients com-
pleted at least the acquisition period. Seven
percent of the clients dropped out after the
first treatment session.
Treatment attenders (partial + complete
attenders) and non-attenders (dropouts at
acquisition) were compared in relation to
sociodemographic data, severity of depen-
dence and associated problems so that pos-
sible attendance predictors could be de-
tected. They were compared by the X2 test
or t-test for independent samples according
to the level of measurement (categorical or
continuous variables). The main findings are
summarised in Table 5. Clients who dropped
out were slightly younger (31 years old) than
those who completed treatment (36 years
old). Although statistically significant (p<0.04)
this difference has little relevance. On the
other hand, very recent cocaine use and the
presence of cocaine related problems were
also associated with a low level of treatment
attendance. While 74% of clients who re-
ported cocaine use in the last 24-48 hours
before the initial assessment dropped out, the
dropout rate of those who had not used co-
caine during that period was significantly
lower (42%) (X2 =7.0 p<0.01).
When considering all clients dependent on
cocaine, it was observed that 40% of those
who dropped out had reported very recent
cocaine use at the assessment interview; this
proportion being lower among those who
attended treatment (about 13%). Among the
clients dependent on cocaine, those who re-
ported only nasal use presented higher at-
tendance than those who reported only
TABLE 2: Social relationships, living arrangement, family and
personal substance abuse and psychiatric disorders history.
Percentage of clients.
Setting INDIVIDUAL GROUP TOTAL
Substance abused Alcohol Drugs Alcohol Drugs Alcohol Drugs
Living arrangement 31 46 36 42 67 88
Sex
alone 16.1 4.3 13.9 9.5 14.9 6.8
family 80.6 93.5 83.3 88.1 82.1 90.9
friends 3.3 2.2 2.8 2.4 3.0 2.3
Relationship with family or significant others
good 29.0 23.9 38.9 35.7 34.3 29.5
regular 54.8 60.8 41.7 40.5 47.8 51.1
bad 3.2 10.9 5.5 14.2 4.5 12.5
not applicable 13.2 4.4 13.9 9.6 13.4 6.9
Positive family history of alcohol/drug abuse
83.9 93.5 91.7 90.5 88.0 92.0
Positive psychiatric antecedents/treatments
29.0 26.1 22.2 33.3 25.4 29.5
Previous treatments for alcohol/drug abuse
67.7 43.5˚ 63.9 38.1˚ 65.7 40.9˚
No differences between settings were detected.
˚ differs from alcohol group (X2 =9.3 p< 0.002)
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TABLE 4: Attendance to treatment - Number and percentage of clients in each category.
Setting    INDIVIDUAL  GROUP        TOTAL
Substance abused Alcohol Drugs Total Alcohol Drugs Total Alcohol Drugs Total
Number of clients 31 46 77 36 42 78 67 88 155
Complete attenders 22.6 15.2 18.2 44.5 19.0˝ 30.8 34.3 17.0˝ 24.5
Dropouts at 54.8 52.2 53.2 33.3 50.0 42.3 43.2 51.1 47.7
acquisition
Partial attenders 22.6 32.6 28.6 22.2 31.0 26.9 22.3 31.9 27.7
(only acquisition)
Attenders (partial + 45.2 47.8 46.8 66.7 50.0 57.7 56.7 48.9 52.2
complete attenders)
Referred 16.1 10.9 13.0 11.1 16.7 14.1 13.4 13.6 13.5
Number of sessions 8 ± 5 6 ± 4 7 ± 4 9 ± 5 6 ± 5˝ 8 ± 5 9 ± 5 6 ± 4˝ 7 ± 5
(average ± sd)
˝ Differs from Alcohol group p<0.002 (X2 test)
** Differs from Alcohol group p<0.002 (Student’s t-test)
TABLE 3: Substance dependence level (according to DSMIII-R criteria) and associated
problems according to physicians assessment. Percentage of clients.
Setting INDIVIDUAL GROUP TOTAL
Substance abused Alcohol Drugs Alcohol Drugs Alcohol Drugs
Dependence level (DSMIIIR)#
light dependence 0 2.2 0 7.1 0 4.5
moderate dependence 29.0 30.4 44.4 42.8 37.3 36.4
severe dependence 71.0 67.4 55.6 50.1 62.7 59.1
Psychological disorders
54.8 32.6¸ 30.6 21.4 41.8 27.3¸
Physical disorders
71.0 43.5¸ 80.6 51.2¸ 71.6 43.2¸
Laboratory tests (ML)
GGT ( 28UI/l)   116 ± 263 22 ± 16 88 ± 164 18 ± 14 101 ± 214 20 ± 15Ì
   % of altered tests 58.1¸ 26.1 63.9¸ 9.5 61.2 18.2
GTO (19UI/l) 35 ± 28 28 ± 45 34 ± 52 17 ± 13 35 ± 43 23 ± 34
   % of altered tests 51.6 44.4 58.3¸ 14.3 55.2 29.5
GTP (24 UI/l) 24 ± 18 27 ± 55 27 ± 21 19 ± 25 26 ± 20 23 ± 43
   % of altered tests 38.7 22.2 41.7¸ 14.2 40.2 18.2
MCV (95 fl) 99 ± 7 96 ± 11 92 ± 6 95 ± 5 98 ± 7 91 ± 9Ì
   % of altered tests 67.8¸ 15.2 55.6¸ 28.6 61.2 21.6
# considering the main substance abused
¸ X2 p<0.001 drug comparison (alcohol vs. drugs) in the same setting
ML= Maximum limit of normality
the means in bold type are out of normal values
Ì  Student’s t-test p<0.05 for drug comparison (alcohol vs. Drugs) in the same setting or in the total sample
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smoking (“crack”), i.v. use or more than one
mode of administration. Although not statis-
tically significant, a higher proportion of treat-
ment attenders reported having had previ-
ous treatment when compared to the dropout
clients. The clients who dropped out were
more likely to have cocaine-related problems
and more relatives with drug problems. Al-
though few clients lived alone, the dropout
rate was higher among them than among
those who lived with family or friends. Among
clients who lived alone only 37.5% complete
the treatment, while 54% who lived with fam-
ily or friends did so.
It was observed that the initial level of de-
pendence, the average weekly number of
drinks and severity of drug consumption in-
dex were not good predictors of treatment
attendance. However, clients who were light
or moderate dependants on alcohol tended
to present with a better attendance rate
(68%) than severely dependent ones (50%).
The average number of drinks/week at initial
assessment was similar for attenders (35 ±
31) and non- attenders group (33 ± 39).
Follow-up data analysis
Follow-up attendance: After analysing the
data regarding attendance to treatment, at-
tendance to follow-up was studied. This pro-
cedure is very important to prevent wrong
conclusions that could be reach if the follow-
up attenders’ population was too much dif-
ferent from the initial sample in relation to
some characteristics. About 70% of the
sample (106 clients) attended follow-up
evaluation, as can be seen in Table 6. The
follow-up evaluation was scheduled to take
place 12 months after assessment. However,
just 8% of the clients attended on that occa-
sion. Most of them (68%) were evaluated
between 12 and 17 months after assessment.
There was no difference between groups in
relation to time elapsed between assessment
and follow-up interviews (individual setting:
16 ± 3 months and group setting 15 ± 3
months).
The average number of effective contacts
needed to schedule a follow-up interview was
similar (2.5 ± 1.8 for individual and 3.1 ±
2.1 for group setting). The number of con-
TABLE 5: Clients previous characteristics and drug history as
predictors of treatment attendance.
ATTENDANCE CATEGORY
VARIABLES Complete partial dropouts p level
attenders attenders at acquisition
Age (years - mean ± sd) 36 ± 11 30 ± 10 31 ± 11 0.04
Recent cocaine use 12% 14% 40% 0.06 (n.s.)
(48 hours before assessment)
Cocaine mode of
administration
oral or nasalsmoked, 67% 45% 28%
injected or more than one 33% 55% 72% 0.03
Previous treatment 66% 49% 46% n.s.
Substance abuse in 24% 28% 48% 0.01
the family
Problems related to 67% 72% 91% 0.03 co-
caine use
Lived alone 8% 7% 13.5% n.s.
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tacts in which it was not possible to talk di-
rectly with clients or their collaterals was not
computed. Up to eight contacts were nec-
essary to “convince” some clients to attend
the interview. Only 29% of individually treated
clients and 31% of group treated ones sched-
uled the follow-up interview at the first con-
tact.
The data collected on assessment from fol-
low-up attenders and follow-up non-
attenders were compared. Follow-up
attenders presented with lower level of sat-
isfaction with their physical health and family
relationship, reported more previous treat-
ments (mainly AA participation) and were
more religious than non-attenders. No sig-
nificant differences in relation to alcohol or
drug use variables were detected. The
samples were not comparable in relation to
attendance to treatment. The average num-
ber of treatment sessions attended were 8 ±
5 for follow-up attenders and 5 ± 4 for fol-
low-up non-attenders. Considering the at-
tendance categories, 61% of follow-up non-
attenders were dropouts and just 4% were
complete treatment attenders. Among follow-
up attenders, 34% had completed the whole
treatment and 24% had completed at least
the acquisition phase. This analysis allowed
us to determine more accurately the kind of
clients to whom our conclusions could be
extended.
Comparison of samples at follow-up
With regards to the 106 followed-up clients,
a comparison of initial data and outcome
measures was made between those treated
individually and those treated in group. Be-
sides, a pre-post treatment comparison was
also made for each group.
The two main broad domains in which
changes were supposed to occur determined
the selection of outcome measures: reduc-
tion of alcohol/drug use and improvement in
personal/social function. To evaluate alcohol
and drug use, both amount (number of drinks)
and frequency (number of days and uses by
day of use) were analysed. The evaluation
of personal/social function was made by
analysing severity of dependence (SADD and
DSMIII-R classification), clients’ self-evalu-
ation and collaterals’ evaluation. The demo-
graphic characteristics (such as age and
socio-economic status), severity of depen-
dence, number of treatment sessions attended
and initial pattern/consumption level of sub-
stances abused were analysed as predictor
variables of “success”.
Alcohol consumption: All measures re-
ferred to a time period of 90 days prior to
interview, both at assessment and follow-up.
Numbers of drinking days, heavy drinking
days, problem drinking days as well as the
TABLE 6: Attendance to follow-up. Percentage of the initial sample
(155 clients) according to setting and substance abused.
FOLLOW-UP ATTENDERS
Substance abused Alcohol Drugs Total
(n at follow-up) (n = 52) (n= 54) (n=106)
INDIVIDUAL 74 61 66
GROUP 81 62 70
TOTAL 78 61 68
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TABLE 8:  Laboratory tests according to group (Part A) and drinking categorization
(Part B) of followed-up clients at assessment and follow-up.
TABLE 7: Alcohol consumption at assessment and follow-up. The values are mean –
standard deviation or percentage of followed-up clients (alcohol and drug dependants).
ASSESSMENT        FOLLOW-UP ANOVA¸
INDIVIDUAL GROUP INDIVIDUAL GROUP F gr F oc F interation
Number of drinking days 47 ± 36 51 ± 31 30 ± 31 # 29 ± 28 # 0.07 30.4˚ 0.56
Number of heavy drinking days 29 ± 34˚ 40 ± 32 11 ± 22 # 20 ± 26 # 4.62˚ 29.1˚ 0.08
Number of problem drinking days 12 ± 21˚ 21 ± 20 4 ± 12 7 ± 13 # 3.46 25.3˚ 2.08
Mean weekly consumption 30 ± 36˚ 43 ± 33 12 ± 22 #˚ 19 ± 22 # 5.12˚ 33.2˚ 0.74
(drinks/week)
Abstinent/moderate rates (%) X2 X2
only alcohol dependants 17% 3% 85%˚ 50% 1.58 6.7˚
alcohol and other drugs dependants 68% 65% 92% 75% 0.04 2.7
all clients 45% 33% 89%˚ 62% 1.22 10.0˚
˚ differs from group treated clients (t-test (means) or X2 (rates) p<0.05) at the same occasion
# differs from the assessment (“t” test for dependent samples or Wilcoxon matched pairs test p<0.05)
¸ Between-within ANOVA Fgr = F group (individual x group); Foc = F occasion (assessment x follow-up); F int = F interaction
(group x occasion)
˚ indicates statistical significance (p<0.05)
Note: If the initial values are considered “covariates” (ANCOVA) no significant differences are detected between individual and
group setting in the variables: mean weekly consumption, number of drinking days, problem drinking days and heavy drinking
days at the follow-up.
Alcohol consumption frequency
(last 90 days)
   Part A - Setting categorization    Part B - Drinkers categorization
ASSESSMENT       FOLLOW-UP  ASSESSMENT FOLLOW-UP
Alcohol Individual Group Individual Group Abstinent/ Heavy Abstinent/ Heavy
dependents Moderate Moderate
MCV (95 fl) 98 ± 9 97 ± 6 97 ± 9 91 ± 4 24 ± 47 97 ± 216Ì 20 ± 15 57 ± 73Ì
GGT ( 28UI/l) 87 ± 119 109 ± 201 34 ± 28 43 ± 60# 25 ± 47 32 ± 30 14 ± 5 27 ± 28Ì
GTO (24 UI/l) 38 ± 37 44 ± 64 32 ± 35 16 ± 10 16 ± 46 28 ± 29Ì 18 ± 16 35 ± 41Ì
GTP (19 UI/l) 20 ± 15 32 ± 22 21 ± 11 22 ± 13 91 ± 12 96 ± 7Ì 90 ± 5 93 ± 7
Drug dependents
MCV (95 fl) 87 ± 17 92 ± 5 90 ± 5 90 ± 6
GGT ( 28UI/l) 19 ± 13 20 ±15 17 ± 9 21 ± 12
GTO (24 UI/l) 19 ± 11 20 ± 19 15 ± 6 21 ± 25
GTP (19 UI/l) 15 ± 9 22 ± 32 19 ± 17 28 ± 39
Part A: # differs from itself at assessment ( Student’s paired “t” test p<0.05)
Part B: Ì differs from abstinent/moderate drinkers (Student’s “t” test or Mann-Whitney “U” test p<0.05) at the same occasions
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mean weekly consumption (drinks/week)
were analysed. Based on these measures, a
categorisation of alcohol consumption (“ab-
stinent/moderate” vs. “heavy”) was made and
used to compare clients treated in group with
those that were individually treated. Alcohol
dependent clients were considered “absti-
nent/moderate” drinkers if they didn’t exceed
20 drinks/week, with no more than 10% of
heavy drinking days (of 5 + drinks).
Clients exceeding either of these cut-offs
were considered “heavy” drinkers. Drinker
categorisation was corroborated by labora-
tory tests, i.e., the clients classified as “heavy”
drinkers presented significantly higher levels
of hepatic enzymes than those considered “ab-
stinent/moderate” (see Table 8).
Table 7 summarises the main results. Group-
treated clients presented slightly higher lev-
els of alcohol consumption, both at assess-
ment and at follow-up. In comparison with
individually-treated clients, they showed a
significantly higher number of heavy drinking
days (at assessment) and mean weekly con-
sumption. However, if assessment levels are
considered “covariates” in follow-up data
analysis, differences between settings disap-
pear. This statistical procedure allows one
to “control” the initial difference in alcohol
consumption levels observed between the
settings. Significant reductions were ob-
served in both settings when assessment data
were compared with follow-up data in the
variables: number of drinking days, heavy
drinking days and mean weekly consump-
tion. Only group-treated clients presented a
significant reduction in the number of prob-
lem drinking days, probably due to its higher
initial level. At follow-up, both settings were
similar.
With regards to client categorisation as “ab-
stinent/moderate” or “heavy” drinkers, signifi-
cantly higher rates of “abstinent/moderate”
were observed in individually treated clients.
This could be partially due to the higher ini-
tial consumption (heavy drinking days and
mean weekly consumption) observed in
group setting clients. If these rates are calcu-
lated in relation to the initial sample (155 cli-
ents), considering all the follow-up non-
attenders as “unsuccessful” cases, the
“alcohol consumption success” rate was 45%
for individually treated clients and 33% for
group treated ones. When considering only
the 106 followed-up clients, the alcohol con-
sumption success rates are 89% (individual
setting) and 62% (group setting).
Laboratory tests: Although a significant
difference was observed between initial and
follow-up alcohol consumption, just GGT
levels were significantly different, at follow-
up, from those observed at assessment. How-
ever, if abstinent/moderate GGT, MCV and
GTP levels were compared between absti-
nent/moderate and heavy drinkers, significant
differences were detected at both phases
(assessment and follow-up) (Table 8), cor-
roborating client categorisation.
Drug consumption: The measures utilised
to evaluate drug use were: IDUS (Index of
Drug Use Severity) (see Appendix 1) and
frequency of use (months per year, days per
month and uses on a typical day of use).
Table 9 shows IDUS and individual ratings
for the most often used drug classes (alco-
hol, cannabis and cocaine) at assessment and
follow-up in both settings. A significant im-
provement in relation to their initial values was
observed in both groups in all variables. Drug
dependants were considered “successful” if
they showed a maximum IDUS of 0.11 (con-
sidering their drug use) or 0.22 (if they just
used alcohol). The “success” in relation to
drug use was 65% of followed-up clients in
the individual setting, and 52% in the group
setting.
The outcome measures related to personal/
social functioning evaluated were: SADD
(Short Alcohol Dependence Data), severity
of dependence according to DSMIII-R and
mean ratings of satisfaction clients attributed
to their physical and emotional health, social
relationships, work, leisure, financial and le-
gal situations.
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TABLE 9: Drug consumption (during the previous year) at assessment
and follow-up. The values are mean  standard deviation or
percentage of drug dependent followed-up clients.
ASSESSMENT          FOLLOW-UP
Drug consumption INDIVIDUAL GROUP INDIVIDUAL GROUP
Index of Drug Severity (IDUS) 0.57 ± 0.3 0.60 ± 0.2 0.25 ± 0.2 # 0.30 ± 0.2 #
Alcohol use
months per year 11 ± 2 11 ± 2 8 ± 5 # 8 ± 5 #
days per month 22 ± 10 19 ± 11 12 ± 11 # 11 ± 9 #
uses per day 9 ± 7˚ 11 ± 4 4 ± 6 # 7 ± 6 #˚
alcohol IDUS rating 2.4 ± 1.4˚ 3.0 ± 1.3 1.2 ± 1.0 # 1.5 ± 1.3 #
Cocaine use
months per year 11 ± 2 9 ± 4 6 ± 5 #˚ 4 ± 4 #
days per month 21 ± 9˚ 16 ± 11 9 ± 11 # 8 ± 10 #
uses per day 3 ± 3 3 ± 3 1 ± 1 # 1 ± 2 #
cocaine IDUS rating 1.8 ± 1.9 1.8 ± 1.9 0.9 ± 1.4 # 0.9 ± 1.5 #
Cannabis use daily frequency
months per year 9 ± 3˚ 7 ± 4 3 ± 4 # 4 ± 5 #
days per month 12 ± 12 10 ± 11 3 ± 5 # 6 ± 9 #
uses per day 2 ± 2 1 ± 1 0.5 ± 0.8 # 0.9 ± 1 #
cannabis IDUS rating 0.8 ± 1 6 ± 1 0.2 ± 0.5 # 0.3 ± 0.7 #
Alcohol and drug use 9% 4% 65% # 54% #
“success” categorisation (%)
(General IDUS ± 0.22)
˚ differs from group treated clients (t-test for independent samples or Mann-Whitney U test p<0.05) at
the same occasion
# differs from the assessment (t-test for dependent samples, Wilcoxon matched pairs test or Mc Nemar
chi-square test p<0.05)
Table 10 shows dependence levels attributed
to clients, according to DSMIII-R criteria,
for each drug, at assessment and follow-up.
Considering the highest level of dependence
(for those who were diagnosed as depen-
dent on more than one drug) the “success”
(partial or total remission) was similar be-
tween settings (50% for individual setting and
45% for group setting). Considering sever-
ity of dependence of each class of drug (scor-
ing -2 for total remission, -1 for partial re-
mission, 0 for abuse, 1 for light dependence,
2 for moderate dependence and 3 for se-
vere dependence), it was observed that both
groups presented significant improvements
when compared to their initial values
(Wilcoxon matched pairs test) with regards
to their alcohol and cocaine but not cannabis
dependence. This could be due to the small
number of cannabis dependants actually
evaluated and to their initial low dependence
level. Furthermore, no difference was found
between group and individual treatment set-
tings. The remission rates of alcohol
dependants were similar between settings
(41% and 38% for individually and group-
treated, respectively) and slightly superior in
the individually-treated drug dependants
(60% for cannabis and 62% for cocaine)
when compared with the group treated ones
(50% for cannabis and 54% for cocaine).
The SADD average scores were similar be-
tween settings. Significant reductions in rela-
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TABLE 10: Severity of dependence measures at assessment and
follow-up.
ASSESSMENT          FOLLOW-UP
INDIVIDUAL GROUP INDIVIDUAL GROUP
SADD 17 ± 10 17 ± 10 11 ± 8¸ 15 ± 8¸
(mean ± standard deviation)
General dependence severity #
light dependence 2 4 14 4
moderate dependence 33 40 16 20
severe dependence 65 56 20 31
partial remission - - 16 14
total remission - - 34 31
Alcohol #
abuse - -
light dependence 12 5 29 5
moderate dependence 3 3 13 30
severe dependence 36 42 16 27
partial remission 48 50 11 25
total remission 30 13
Cocaine #
abuse
light dependence 8 12
moderate dependence 4 12 11 11
severe dependence 32 36 19 23
partial remission 64 52 27 8
total remission 35 46
Cannabis
abuse 22 17 20 -
light dependence 22 - 25
moderate dependence 44 33 20 -
severe dependence - 25
partial remission 11 17 20 25
total remission 33 40 25
¸ differs from their initial values
# Ratings between -2 (total remission) and +3 (severe dependence) were attributed to the subsequent
levels of dependence. Wilcoxon matched pairs test detected significant differences between assess-
ment and follow-up evaluation for both setting groups.
tion to initial levels were observed at follow-
up for both groups.
Satisfaction scores: The clients were re-
quested on both occasions to grade their
satisfaction levels in the following areas:
physical health, emotional health, work/
school, social, familiar, financial and legal situ-
ation, giving each item a grade between 0
and 10. The mean values are presented in
Table 11. Group-treated clients reported sig-
nificant improvements in most of the areas
but family, social and legal, while individu-
ally-treated clients did not present significant
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improvements just in the legal area. It should
be taken into account that most of the clients
did not present legal problems at assessment.
General success rates: A general classifi-
cation of clients as “successful” or ‘’unsuc-
cessful” was made based on alcohol and drug
consumption data. For alcohol dependent
clients, the categorisation of consumption
(abstinent/moderate) was used as the “suc-
cessful” measure. For drug dependent cli-
ents, IDUS and alcohol consumption
categorisation (in cases of both alcohol and
drug dependence) were taken into account.
Clients were considered “successful” if they
were abstinent/moderate in relation to alco-
hol and presented an IDUS lower than 0.11
(drug use) or 0.22 (just alcohol use). The
rates of “success” are showed in Table 12.
The settings presented similar rates in rela-
tion to drug use but alcohol dependent cli-
ents who were individually treated improved
more than group-treated clients did. How-
ever, as discussed above, this may be attrib-
utable to their high initial alcohol consump-
tion levels.
Clients self-evaluation: Clients rated
themselves in relation to assessment as “suc-
cessful”, “improved” or “unimproved/worse”.
Forty-four percent of individually-treated cli-
ents and 24% of group-treated clients con-
sidered themselves “successful”. The “im-
proved” category was chosen by 52% of
individually-treated and 69% of group-
treated clients. The treatment and their per-
sonal effort were considered determinant fac-
tors in their improvement/success by 75%
of individually-treated clients and by 82% of
group-treated ones. The correlation between
“success” according to client’s self-evalua-
tion and consumption criteria (alcohol
categorisation for alcohol dependants and
IDUS for drug dependants) was significant
in spite of being low (Spearman r=0.25 for
alcohol and 0.24 for drug dependants). The
lack of success was attributable to lack of
personal effort by 100% of alcohol depen-
dent clients (in both settings). When consid-
ering drug dependent clients 75% of individu-
ally-treated and 67% of group-treated clients
attributed failure to lack of personal effort.
Collateral evaluation: Most of the
collaterals who attended were clients’
spouses, who reported having daily contact
with client. According to the information pro-
vided by them, the effectiveness of both
groups (individual/group) was also consid-
ered similar. They classified the client’s im-
provement after treatment into three catego-
ries: “unimproved”, “improved” or “successful”.
TABLE 11: Satisfaction scores attributed by clients to several areas of
life at assessment and follow-up.
ASSESSMENT          FOLLOW-UP
INDIVIDUAL GROUP INDIVIDUAL GROUP
Physical health 6 ± 1 6 ± 1 8 ± 1˚ 7 ± 1˚
Emotional health 6 ± 1 5 ± 1 8 ± 2˚ 7 ± 1˚
Family relationship 6 ± 2 6 ± 2 8 ± 2˚ 8 ± 1
Social relationship 8 ± 2 8 ± 2 8 ± 2 8 ± 2
Work/School 6± 2 6 ± 2 8 ± 2˚ 8 ± 2˚
Financial 5 ± 1 5 ± 1 5 ± 2 5 ± 2˚
Leisure 4 ± 2# 5 ± 2 6 ± 2˚ 6 ± 2˚
Legal situation 10 ± 0 10 ± 0 10 ± 0 10 ± 0
˚ differs from their assessment values (Wilcoxon test)
# differs from group treated clients at the same occasion ( Mann-Whitney test)
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TABLE 12: Summary of results, according to various success criteria (alcohol and drug
consumption, severity of dependence(DSMIII-R), clients self-evaluation and collaterals
evaluation. Percentage of the 106 followed-up clients. Between brackets the percentage
of the initial sample, being all the not-followed up clients considered unsuccessful.
Results are presented in Table 12. “Success”
rate was slightly higher in the group setting
(36%) than in individual setting (29%), although
no significant statistical differences were de-
tected. Considering only alcohol dependents,
70% of the collateral’s rating of “success” agreed
with the alcohol consumption categorisation. On
the other hand, low agreement (32%) was de-
tected regarding drug dependants. The main
disagreements were due to clients considered
“unimproved” (IDUS rating > 0.22) by the
consumption categorisation and “improved” by
collaterals.
Predictors of outcome: “Successful” or
“improved” clients were compared with the
“unimproved” ones in relation to their initial
characteristics in attempt to identify predic-
tor variables for “success”. The first variable
tested was treatment attendance. Outcomes
of treatment attenders were compared with
those of treatment non-attenders, in order to
evaluate the contribution of attendance to
treatment to the observed outcomes. These
data are summarised in Table 13. Outcomes
varied depending on the main substance
abused. Regarding alcohol dependent clients,
it was observed that 96% of followed-up
individually treated clients who had com-
pleted the treatment were considered “suc-
cess”/”improved”, while the same was true
for 82% of those who dropped out presented
the same result. For group-treated clients,
the same comparison showed a smaller dif-
ference in success between those who com-
pleted treatment (68%) and the dropouts
(47%). However, the difference in success
rate between settings was not statistically sig-
nificant if the initial values were used as co-
variates (ANCOVA).
The number of attended sessions, the sever-
ity of alcohol consumption, the weekly aver-
age alcohol consumption, the heavy drinking
days and log of GGT levels showed signifi-
cant correlations with success at follow up
 SUBSTANCE ABUSED        ALCOHOL       DRUGS     TOTAL
SETTING INDIVIDUAL GROUP INDIVIDUAL GROUP INDIVIDUAL GROUP
Success criteria
Alcohol consumption 85¸ 50 92 75 89 (60)¸ 61 (41)
(abstinent/moderate)
successful 55¸ 44 80 62 69 (47)¸ 52 (35)
improved 30¸ 7 12 12 20 (14) 10 ( 7)
Alcohol and drug consumption (IDUS) 83¸ 57 52 46 65 (43) 52 (36)
Alcohol dependence (remission) 56 41 - - 40 (27) 37 (25)
Cocaine dependence (remission) - - 64 56 64 (44) 56 (38)
Cannabis dependence (remission) - - 60 66 60 (40) 66 (45)
Clients’ self-evaluation
successful 44 24 39 27 42 (29) 25 (17)
improved 52 69 39 65 45 (31) 67 (46)
Collateral evaluation
successful 30 27 28 43 29 (20) 36 (24)
improved 52 50 50 40 51 (35) 44 (30)
¸ differs from group-treated clients
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TABLE 13: Outcomes measures comparison between treatment attenders and
non-attenders.
ALCOHOL DRUG REMISSION OF
CONSUMPTION CONSUMPTION DEPENDENCE
(abstinent/moderate %) (IDUS > 0.22) (DSMII-R)
SETTING INDIVIDUAL GROUP INDIVIDUAL GROUP INDIVIDUAL GROUP
Treatment attendance
attenders 96˚ # 68 78˚ 60 54 54
non-attenders 82 47 50 37 46 30
˚ differs from non-attenders
# differs from group treated
— the higher the initial alcohol consumption,
the lower the success. A logistic regression
multivariate analysis showed that the GGT
level and the number of sessions were the
best predictors of outcome. The smaller the
number of sessions attended and the higher
the GGT levels log, the lower the success.
Regarding drug dependent clients attendance
to treatment and index of drug consumption
(IDUS) were considered as predictors of
success. The stronger the adherence to treat-
ment and the lower the IDUS, the higher the
success.
How were the results
used?
The initial questions were answered by the
data analysis. With regards to setting influ-
ence, an interaction was observed with drug
type. Alcohol dependent client treated in
group tended to have higher treatment at-
tendance than those treated individually.
However, their outcomes were similar when
initial levels were controlled. This informa-
tion should be taken into account when rec-
ommending the treatment setting to a client.
Considering that attendance is an important
predictor of outcome, group setting should be
preferably indicated for alcohol dependent cli-
ents. On the other hand, drug dependants hardly
attended treatment, independently of setting, and
this is a point worthy of attention/intervention:
what could be done to increase their compli-
ance to treatment?
Since the results indicated there were no sig-
nificant differences in relation to “success”
between the two settings, both options were
maintained. The group format was chosen
as the “standard” kind of therapy to be of-
fered. However, the “individual” option was
maintained in order to supply specific needs,
according to clients’ needs/preferences and
the therapist’s diagnosis. It was also decided
to allow the drug dependent client to choose
the setting.
It was decided to implement a motivational
program to increase early compliance to
treatment, since it was observed that most
dropouts occurred in the very beginning of
treatment. Furthermore, since substance
abuse in the family was a predictor of non-
success, it was decided to include a family-
functioning diagnosis in the assessment as a
routine and the possibility of family therapy
when necessary.
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Its your turn
What are the strengths and the weaknesses of the presented case example? List three posi-
tive aspect and three negative aspects:
Strengths of the case study
1
2
3
Weaknesses of the case study
1
2
3
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Appendix 1 for case example
The IDUS (Index of Drug Use Severity) was
proposed by Wilkinson and LeBreton (1986)
and took into account the number of drug
classes used and the amounts of each drug
used. This was made according to the guide-
lines proposed by those authors (see chart),
using the data obtained by means of the Psy-
choactive Drug Use History table.
Alcohol Cannabis Other drug classes
0 = abstinent No use of drugs from this class during past year
1 = low ≤ 20 drinks/week and ≤ 4 joints/week and ≤ 1 use/month
problem still? = No ≤ 2 joints/day by use
and problem still? = No
2 = intermediate ≤ 10 drinks/day and < 10 joints/week > 1 use/month but
≤ 42 drinks/week < 1 use/week
3 = high > 10 drinks/day or ≥ 10 joints/week ≥ 1 use/week
> 42 drinks/week
4 = “outrageous” Very high level of consumption, even within this sample.
At rater’s discretion
Index of drug use severity (IDUS)
Guidelines for ratings of drug use in past year     (Wilkinson and LeBreton, 1986)
The rating for each of the main substances
abused (alcohol, cocaine and cannabis) and
the general index (IDUS) were considered
in the analysis. The IDUS was obtained by
adding scores of eight classes and then di-
viding the sum by 8, converting it to a mean
rating per drug class for each client, on a
5-point scale (0 to 4).
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Case example of an
outcome evaluation
The National Treatment Outcome
Research Study (NTORS): inception
and implementation of a major
treatment evaluation study in the UK
by
Michael Gossop
John Marsden
Duncan Stewart
Petra Lehmann
Carolyn Edwards
Alison Wilson
Graham Segar
National Addiction Centre
4 Windsor Walk
London, UK
SE5 8AF
Who was asking the
question (s) and why
did they want the
information?
In 1994, the Department of Health in the UK
established a Task Force to review the ef-
fectiveness of the national services for drug
misusers. Its specific goal was “to conduct a
comprehensive survey of clinical, operational
and cost effectiveness of existing services for
drug misusers; to review current policy in
relation to the principal objective of assisting
drug misusers to achieve a drug free state,
and the secondary objective of reducing
harm caused to themselves and others by
those who continue to use drugs; to make
recommendations where appropriate and to
report to Ministers” (Task Force Report,
1996). The Task Force committed itself to
base its deliberations as far as possible upon
firm research evidence derived both from
within the UK and from other countries.
The authors alone
are responsible for
the views
expressed in this
case example.
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One of the first actions of the Task Force
was to commission the National Treatment
Outcome Research Study. NTORS is a
large-scale, multi-site, prospective study of
treatment outcome conducted with a cohort
of more than 1000 people who entered drug
misuse treatment services in England during
1995. It was specifically commissioned to
provide evidence of the effectiveness of ex-
isting national drug misuse treatment services.
NTORS is the largest prospective study of
treatment outcome for drug abusers ever
conducted in the UK. NTORS owes much
to other large scale studies of treatment out-
come which were conducted in the United
States. These include DARP (Simpson and
Sells, 1990), TOPS (Hubbard et al., 1989),
and the six cities study of methadone main-
tenance (Ball and Ross, 1991). Such studies
have demonstrated that the treatment of drug
abuse problems can be effective. However,
the problems of generalising from studies
carried out in other countries are consider-
able. The characteristics of American drug
abusers could be expected to differ in many
respects from those in the UK, as will the
types of treatment services and interventions
which are provided. The problems associ-
ated with drug abuse are complex and the
treatment of such problems is difficult. In or-
der to improve the effectiveness of treatment
interventions for drug problems, policy plan-
ners, service purchasers and providers, and
researchers all need a clearer understanding
of the many factors that contribute towards
the success of treatment.
The significance of NTORS is in part due to
the fact that it has been designed and imple-
mented as a national study; investigating
treatment programmes from all parts of En-
gland. Its design is comprehensive, looking
in detail at the social and psychological char-
acteristics of clients, and at a wide range of
treatment operation factors in relation to
multiple measures of treatment outcome. For
these reasons, the results of NTORS will be
of great interest in terms of their contribution
to our scientific understanding of treatment
outcome. The results will also provide valu-
able data about the impact of the national
treatment responses upon drug abuse prob-
lems and be relevant to the needs of policy
planners, purchasers and providers in help-
ing to develop and strengthen drug services
and interventions.
The primary purpose of NTORS is to pro-
vide empirically derived information about the
nature of the existing national treatment re-
sponses and about the changes in behaviour
which occur among problem drug users who
have been treated within those services.
More specifically, NTORS has been designed
to provide answers to the following ques-
tions:
1 What are the characteristics of clients
entering the national treatment
programmes included in the study?
2 What are the key structural and opera-
tional components of the NTORS treat-
ment programmes and interventions?
3 What types of problems are presented by
clients in NTORS and how severe are they?
4 What sorts of changes occur subsequent
to treatment?
5 To what extent are these initial changes
maintained over time?
6 What is the relationship between client
characteristics and observed outcome?
7 What is the relationship between treatment
structure and process variables and ob-
served outcome?
What resources were
needed to collect and
interpret the
information?
The project was run from the National Ad-
diction Centre at The Maudsley Hospital in
London. The Project Director was Dr.
Gossop. The project was co-ordinated in
London by Dr Marsden with two research-
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ers and a research administrator. Due to the
national scale of the study two further re-
searchers were based in Manchester. A to-
tal of 54 agencies were selected for partici-
pation in NTORS. These included 16
methadone maintenance programmes, 15
methadone reduction programmes, 15 resi-
dential services and 8 in-patient units. Dur-
ing the selection of agencies and after par-
ticipation in the project had been agreed,
NTORS researchers made visits to all of the
participating agencies. The purpose of this
visit was to conduct training with the MAP
interview procedures and to set up neces-
sary administrative procedures to ensure
agencies would be in regular contact with the
two research bases. Researchers encouraged
one person at each agency to take responsi-
bility for the on-site co-ordination of the
project. All staff who were involved in con-
ducting the interviews were trained in the use
of the instrument and client response cards.
Training manuals were also supplied to each
agency for guidance about procedures. Sites
were provided with specially designed post-
ers and leaflets to advertise the study to cli-
ents and to encourage the identification of
clinical workers with the project.
Close liaison between the research team and
the clinical agencies has been an issue of pri-
mary importance in ensuring the success of
the project. This issue deserves emphasis as
one of the “hidden” factors behind the imple-
mentation of NTORS. Without the commit-
ment, active co-operation and assistance of
the agencies, it would have been impossible
to conduct this study.
How were the data
collected?
NTORS monitors the progress of clients who
are starting a treatment episode in one of four
treatment modalities (specialist inpatient
treatment, residential rehabilitation, metha-
done maintenance, and methadone reduction
programmes). In NTORS, the term ‘modal-
ity’ is used to refer to a broad category of
treatment intervention. Within this category
it is accepted that there may be some, and
possibly considerable variation. However, the
treatment interventions included within each
modality should have general defining char-
acteristics and common features, such as the
treatment setting within which the interven-
tion is provided, and/or the goals of treat-
ment, and/or the types of procedures used
(e.g. the prescription of substitute drugs).
The research design used by NTORS is
based on a tradition of programme evalua-
tion and longitudinal outcome research de-
veloped in the United States. The study is
naturalistic and causal inference will be
achieved through measurement of key vari-
ables and comparison of treatment samples
on the basis of pre- and post-treatment out-
come measures. This design was chosen in
preference to a randomised control design.
Individual differences among clients seeking
drug abuse treatment are often so great that
it renders the assembling of matched treat-
ment and control groups untenable; truly ran-
dom designs are extremely difficult if not im-
possible to implement in a field setting;
withholding treatment from a control group
cannot be ethically justified; and client
samples based upon random selection will
behave differently from clients selected
through clinical need and motivation for treat-
ment thus creating an “experiment” which is
not relevant to real treatment circumstances.
Useful evaluation studies require longitudinal
data and, in NTORS, the client’s own baseline
measures are used as a control condition to
assess change. In a naturalistic or quasi-ex-
perimental design such as that used in
NTORS, pre-existing differences in client
characteristics as well as differences in so-
cial and environmental circumstances may
explain part of the differences observed in
outcome across programmes. NTORS mea-
sures such differences precisely so that they
can be taken into account in explaining what
sorts of factors influenced the observed out-
comes.
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The conceptual approach underpinning
NTORS sees addictive behaviour change as
a dynamic process in which multiple influ-
ences determine the outcome of any treat-
ment intervention (Gossop, 1992). This ap-
proach has guided the overall design of the
study and the specific selection of measures.
NTORS sees treatment outcome as depen-
dent upon the action and interaction of four
types of factors. These are:
1 the type and severity of drug use behaviour
(including type of drug used, duration of
use, route of administration, severity of
dependence);
2 personal functioning (e.g. readiness for
change, attitudes and beliefs, psychologi-
cal health, personal coping skills);
3 treatment effects (e.g.; treatment setting,
duration and intensity of treatment, type
of intervention, therapist effects);
4 social/environmental factors (including
social resources, relationships influences
and supports).
Services of potential usefulness to NTORS
were selected after giving consideration to: the
capacity of the agency, and in particular, its
ability to recruit a sufficient number of cases
to NTORS within the restricted time available
for recruitment: capacity was defined in terms
of the number of new cases presenting to the
services in the last month; the location of the
service: NTORS required agencies which were
located throughout England but which were
also located in areas which were representa-
tive of areas in which drug problems and drug
treatment services were prevalent.
In general, the former criterion was used to
identify agencies which would potentially be
able to recruit at least 20 new clients into treat-
ment during the recruitment phase of the
project, and the latter, to attempt to recruit agen-
cies from health regions across the country.
The Maudsley Addiction Profile (MAP) is
a set of structured research interviews
which were developed specifically for the
NTORS project. The MAP profiles the
social circumstances, key problems and
experiences of drug users at treatment en-
try and at the follow-up points during and
after leaving treatment. MAP interviews
were designed to be used by clinical and
agency staff without a research training.
Efforts were made to balance the infor-
mation needs of the study against the bur-
den on staff time in interviewing clients.
Post-treatment interviews were conducted
by trained independent interviewers from
the Office for National Statistics.
Development of the MAP proceeded in
three stages. First, an initial pool of mea-
sures were compiled across three
overarching measurement domains: sub-
stance use, physical and psychological
health, and social functioning and life con-
text. Second, a further set of measures was
incorporated which concerned psychologi-
cal aspects of drug use, motivation for
treatment, and coping strategies. These
latter items were included to assess their
value in understanding the manner in which
clients respond to treatment as well as to
longer term recovery. Draft versions of the
MAP interviews were piloted with samples
of drug users in several treatment services.
This piloting led to further refinements and
improvements in item structure and inter-
view design. Two specific modifications
were made. On the basis of experience
derived from the feedback from pilot in-
terviews, a response card booklet was
prepared to assist interview completion for
each of the MAP instruments. Another
design modification concerned questions
about involvement in criminal activities and
with the criminal justice system. Given the
sensitivity of this topic, the respondent was
given the choice of using a self-completion
questionnaire.
A training strategy was implemented by the
NTORS team to assist agency staff in the
administration of the MAP interviews. In-
struction manuals were prepared describing
the rationale and structure of the interviews
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with detailed notes on the interview proce-
dure and item completion. The research team
then conducted on-site training sessions at
each agency with staff to ensure familiarity
with the interviews. Subsequent feedback
from the agencies suggested that this proce-
dure was valuable both as a specific learning
exercise and also for enhancing working links
between NTORS and treatment staff. A
pack of materials was prepared for each
participating agency containing information for
clients, consent forms, MAP interviews and
response cards, and enrolment forms. A
single “at-a-glance” information sheet for
agency staff was also designed describing the
procedure to follow for client enrolment and
completion of the MAP-1 interview.
As implemented in NTORS, the MAP-1 is
a 62 item structured interview of approxi-
mately 45 minutes duration. It comprises 7
sections: 1. background information; 2. drug
and alcohol use; 3. change motivation and
coping; 4. health; 5. relationships; 6. legal
issues; 7. treatment.
Six scales which have been used in previ-
ous research were selected and adapted
to assess issues 1-6. A full description of
the development of these measures is avail-
able from the National Addiction Centre
(contact Drs Gossop and Marsden). The
MAP scales have established validity and
reliability and will facilitate comparison of
NTORS data with previous research. New
items were developed specifically for the
study, particularly within the legal and treat-
ment sections. The legal section of the
MAP looks in detail at involvement with
the criminal justice system and criminal
activity. The treatment section records the
clients’ treatment history and use of hos-
pital, residential and community services
for medical, psychological and substance
use problems. Successive MAP interviews
administered during and after the index
treatment episode comprise a core set of
repeated measures from the above do-
mains.
NTORS employs a design of time-anchored
follow-ups following admission. Data is col-
lected at five interview points: (a) intake; (b)
six months; (c) one year; (d) 2-3 years; and
(e) 4-5 years from intake. The intake, and
for clients still in treatment, six month inter-
views were conducted by treatment staff at
the agencies. Follow-up interviews with cli-
ents who had left treatment before six
months, and all remaining interviews were
carried out by independent researchers from
the Office for National Statistics (ONS). At
each interview point, clients were asked to
provide contact addresses (personal ad-
dress, family/friends, doctor, etc.) to enable
location for future follow-up interviews. Fol-
low-up rates of at least 70% were expected
at each point in the study.
Agency staff approached all eligible clients
starting treatment at the agency between
February 27th and July 31st 1995, and in-
vited their participation into the study. Cli-
ents were eligible for an NTORS intake in-
terview providing all of the following criteria
were met:
• starting a new treatment episode;
• presenting with a drug-related problem
(other than alcohol);
• able to provide an address in the UK for
follow-up;
• not a previous client of NTORS.
1,110 eligible clients were interviewed over
a five-month recruitment period for inclusion
in the study. Of these, 35 did not provide
sufficient locator information to allow follow-
up and a revised sample base of 1075 cli-
ents was established. The number of clients
recruited to each treatment modality is shown
in Table 1.
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The largest number of clients was recruited
from the methadone maintenance
programmes. This was mainly due to the in-
clusion of the eight pilot structured metha-
done maintenance projects within the
NTORS framework. A total of 350 clients
were recruited into these methadone main-
tenance treatment programmes within the
NTORS recruitment period. It should be
noted that within study resources, verifica-
tion of self-reported drug use was provided
by urinalysis. Urine was collected from cli-
ents for screening at 25 programmes (selected
on a one-in-two sampling basis), with
samples taken at each interview. Initial de-
tection of opiate, methadone, amphetamines
and cocaine metabolites were performed with
enzyme immunoassays (EMIT), confirmed
with thin layer chromatography procedures.
Concordance between self-reported drug use
and urinalysis were high. For example, at the
six month follow-up, concordance was as
follows: heroin (92%); cocaine (93%); am-
phetamines (97%).
How were the data
analysed?
At present, the project is still at an early stage.
In this paper, the intake-follow-up compari-
sons are presented as basic rates and pro-
portions, with changes assessed by the
McNemar test. More detailed and system-
atic analyses employing multivariate proce-
dures will be utilised in subsequent presen-
tations. NTORS assesses a wide array of
client behaviours and other measures which
are assessed on a number of different occa-
sions. Various statistical procedures will be
employed for the analysis of longitudinal data.
For example, the procedure used to asses
change over time in each continuous depen-
dent variable is multivariate analysis of co-
variance with time (i.e. repeated measures)
being regarded as a within subjects factor.
For this analysis of variance various effects
of treatment, time, and treatment x time in-
teractions are estimated.
What did they find out?
A basic demographic profile of the NTORS
cohort is shown in Table 2.
Opiates, benzodiazepine and stimulants (no-
tably cocaine and amphetamines) were
among the drugs most commonly used by
people presenting for treatment in recent
years. Individuals approaching UK treatment
services most often present with opiate prob-
lems (and specifically with heroin depen-
dence), although the misuse of stimulant
drugs and benzodiazepine is not uncommon
(Strang and Gossop, 1994). However, the
classification of drug problems according to
the use of single substances can be mislead-
TABLE 1: Clients recruited to NTORS by treatment type
Treatment Type Number of clients recruited % of cohort
Inpatient 122 11.3%
Residential Rehabilitation 286 26.6%
Methadone maintenance 458 42.6%
Methadone reduction 209 19.4%
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ing. Very few drug abusers who require treat-
ment confine themselves to the use of a single
substance, and many tend to be heavy and
problematic users of more than one drug. The
identification of someone as a heroin addict
should not be taken to imply that the drug
problem is solely that associated with the use
of heroin. For example, there has been in-
creased problematic use of cocaine and ben-
zodiazepines by opiate users in the UK in
recent years (Strang et al. 1994).
The clients who received treatment within the
NTORS agencies were almost all multiple
users. Few drug users restricted their
behaviour to one drug, though dependence
upon heroin was the single most common drug
problem. The average length of heroin use for
the cohort was 9 years (standard deviation =
5.8 years). The relative chronicity of the drug
abuse problems experienced by the NTORS
clients must be borne in mind when evaluating
the impact of treatment.
In the three-month period before starting
NTORS treatment, more than half of the
cohort reported using benzodiazepines. Ben-
zodiazepines were the second most fre-
quently used type of drugs to heroin and the
opiates. While approximately one in five cli-
ents were using benzodiazepines every day,
a further one in six were using them regularly
each week and a further 17% on an occa-
sional basis. There may be significant direct
harm associated with the use of these drugs,
particularly when they are used by intrave-
nous injection. For instance, a good deal of
national concern has been linked to the in-
jection of temazepam preparations.
TABLE 3: Illicit Drug Use
Drug %
Heroin 87
Illicit methadone 49
Benzodiazepines 54
Cocaine powder 18
Crack cocaine 35
Amphetamines 24
Stimulant drugs were used by many NTORS
clients. More than one third of the clients re-
ported using crack cocaine in the period prior
to starting the NTORS treatment episode.
Almost a quarter reported using amphetamine
sulphate. The frequency of crack cocaine use
was higher than cocaine powder. Forty-nine
clients used crack cocaine every day in the 3
months before intake; a further 130 (12%)
clients were regular weekly users of crack
and 199 reported using the drug though on a
less than weekly basis. It was comparatively
rare for the NTORS cohort to be daily users
TABLE 2: Personal demographic profile at treatment entry
Methadone Methadone
Characteristic Inpatient Residential Maintenance Reduction
(n = 122) (n = 286) (n = 458) (n = 209)
Gender
% Males 77% 74% 72% 73%
Mean Age 30 yrs. 29 yrs. 30 yrs. 27 yrs.
Race/ethnicity
% White-UK 94% 88% 90% 93%
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of cocaine powder; only 1% used daily, al-
though 17% used it on an occasional or
weekly basis. There is considerable concern
about the prognosis for drug misusers with
serious stimulant problems, and future analy-
ses of the NTORS data will permit investi-
gation of different patterns of drug use in re-
lation to treatment outcome.
Overall, 62% of the cohort reported that they
had injected a drug in the three months prior
to treatment. There were no statistically sig-
nificant differences between men and women,
nor differences across treatment modality.
The usual route of administration was intra-
venous for 59% of the clients who had used
heroin three months prior to treatment, 40%
of the heroin users smoked the drug. Co-
caine powder and amphetamines were also
frequently injected, approximately half of the
clients who had used these drugs in the pre-
vious three months had injected them.
Injecting drug users are at risk of HIV and
other infections, including the hepatitis infec-
tions B, C and D, through the sharing of in-
jecting equipment as well as through unsafe
sexual behaviours. During the three months
prior to treatment, 156 clients (15%) reported
using a needle or syringe after someone else
had used it. There was a higher rate of pre-
treatment needle and syringe sharing amongst
female drug users where proportionately
more females than males reported using a
needle or syringe after somebody else had
already used it. This pattern of needle shar-
ing has been observed in clinical populations
and may be sharing between partners. Shar-
ing rates also differed significantly across
treatment modality. Clients in residential
treatment were more likely to report having
used a needle or syringe after somebody else
had used it.
In the three months prior to intake, the ma-
jority of the cohort reported a range of gen-
eral health problems. Specific symptoms in-
cluded sleep disturbance (81%); weight loss
(68%); injection-related abscesses and infec-
tions (15%); chest pains (38%); and periph-
eral nervous system disorders (37%). Dental
problems (frequently involving pain) were re-
ported by more than half of the entire cohort.
Similarly, many clients reported a range of
psychological problems before intake. Dur-
ing the three months before treatment, about
two thirds reported depressed mood or anxi-
ety, and more than 300 clients reported
thoughts of suicide. These problems of de-
pressed mood and suicidal thinking were sur-
prisingly common within the cohort. It is a
matter for concern, and indicative of the con-
siderable distress of the NTORS clients that
such a large proportion of them were thinking
of ending their lives.
The rates of criminal activity among the co-
hort was high. More than 70,000 separate
criminal acts were reported by the NTORS
clients during the three months prior to treat-
ment. Shoplifting was the most commonly
reported illegal activity with more than one
third of the cohort having committed at least
one such offence before intake. Crimes of
fraud and burglary were also quite common,
and more than a quarter of the cohort re-
ported crimes of selling drugs. Almost three
quarters of the full cohort had been arrested
in the two years before intake (again, most
commonly for shoplifting offences). About
one third had been arrested for a drug of-
fence. There were differences in profiles of
criminal activity between clients entering the
different treatment modalities. The highest rate
of theft offences, for instance, was reported
by the clients who entered the residential re-
habilitation services. Similarly, the highest rate
of imprisonment during the three months
prior to recruitment was also reported by the
rehabilitation clients.
Similar differences were found for previous
contact with addiction and other health care
services. The addiction treatment histories of
drug users typically reveal multiple help seek-
ing from different drug treatment services. The
service use history that each drug user brings
to addiction treatment may have an impor-
tant bearing on the impact of the current treat-
ment. Rates of previous psychiatric treatment
were highest among residential and inpatient
clients. A higher proportion of drug users
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entering the inpatient and residential modali-
ties had received past hospital psychiatric
treatment when compared to the community
methadone programmes (inpatient = 14%;
residential = 15%; methadone maintenance
= 8%; methadone reduction = 6%). Clients
of residential programmes were also more
likely to have received community psychiat-
ric treatment (21%); and also to report re-
ceiving treatment from an Accident and
Emergency department (64%). Overall,
about half of all the NTORS clients had been
in contact with an Accident and Emergency
department. This latter finding deserves some
attention. We are surprised at the extent to
which the NTORS clients in general and the
rehabilitation clients in particular had been in
contact with hospital A & E services. This
finding alone draws attention to the consid-
erable demands which clients with serious
substance use problems make upon health
care resources other than the specialist ad-
diction treatment services.
Impact of Treatment at Six
Months
NTORS is a prospective study which will
provide follow up information on the clients
during a five year period after entering the
target treatment. During the full five-ear fol-
low-up period, presentations of the data will
be made at various points. The results will
show the immediate impact of treatment upon
substance use and other problems, continu-
ing benefits at one year follow-up, and
longer-term gains throughout the five-year
period. At present, the project is still at an
early stage. In this paper, outcome data are
presented as basic rates and proportions.
More detailed and systematic analyses em-
ploying bivariate and multivariate procedures
will be utilised in subsequent presentations.
809 clients were interviewed approximately
6 months after treatment intake (75.3% of
the cohort).
We have avoided making any direct compari-
sons between modalities in terms of their out-
comes. We would caution the reader against
attempting any such relative comparisons. The
important differences that are known to exist
between clients at intake provide one com-
pelling reason to avoid simple comparisons of
outcomes across modalities.
Following implementation of NTORS, the UK
Government Task Force was informed of ini-
tial improvements after treatment entry for avail-
able data in a report submitted to the Depart-
ment of Health in October 1995. A summary
of these results is in the public domain (Gossop
et al., 1996). There were significant increases
in the number of clients who were drug-free
and who had been abstinent for at least the pre-
vious 30 days. At the cohort level, abstinence
rates for heroin improved from 15% at intake
to 42% at follow-up; for crack-cocaine from
65% to 78.5%; for non-prescribed methadone
from 52% to 80%; and from 32% to 41% for
alcohol. In many respects, the use of heroin or
other opiates is frequently a focus of treatment
interventions and it is encouraging that the use
of these drugs showed substantial reductions
at follow-up. Marked reductions in heroin use
were found among clients in all modalities at
six-month follow-up. As a further illustration of
changes in the pattern of drug consumption,
regular use of heroin and cocaine (in this case,
operationally defined as weekly or more fre-
quently), reductions from intake to six months
by treatment modality, are presented in Figures
1 and 2 (reproduced from Gossop et al., 1997).
The importance of injecting behaviours in
general, and the sharing of injecting equip-
ment in particular, have been clearly speci-
fied as priority drug problem behaviours in
the UK. The NTORS findings regarding
these behaviours are, therefore, of consid-
erable importance. For the full cohort, there
were significant reductions both in injecting
rates and in the sharing of injecting equip-
ment. The rate of injecting fell from 61% (n
= 497) to 39% (n = 314). The sharing of
injecting equipment fell from 14.5% (n = 117)
to 5% (n = 41) at six-month follow-up.
Among those who were injecting drugs at
intake, sharing fell from 23.5% to 7%. Sig-
nificant improvements were observed among
clients who were treated in all four of the
NTORS modalities. Figures 3 and 4 show
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rates of injecting and sharing needles and
syringes respectively at the two interview
points. The reductions in needle sharing
behaviours can clearly be seen in Figure 4.
At admission, many of the cohort were regu-
larly drinking excessive amounts of alcohol.
Among regular drinkers, average daily alco-
hol consumption on a typical day fell from
17 units at intake to 8 units at follow-up. For
daily drinkers, average consumption fell from
24 to 12 units. The percentage of daily drink-
ers who were drinking 10 units or more fell
from 75% to 41%.
For the health domains, there were also
marked improvements in the prevalence of
physical and psychological health symp-
toms (anxiety and depression). For ex-
ample, the percentage of clients who re-
ported feeling hopeless about the future
fell from 62.5% to 44%; clients having
suicidal thoughts fell from 29% to 16%,
and clients who were extremely troubled
by suicidal thoughts fell from 10% to
4%. There were also reductions in crimi-
nal activity at follow-up. Rates of crimi-
nal activity, excluding drug selling, are
shown in Figure 5.
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How did they use the
information?
NTORS is still at a comparatively early stage.
Data have now been collected on clients at
the 6 month and 12 month follow-up points.
Detailed analyses of these data are being
conducted and full reports on the outcomes
observed at these points are currently in
preparation. The initial results from NTORS
point to substantial improvements in all tar-
get problem behaviours immediately after
starting treatment. Data presented in this pa-
per show that the NTORS cohort reported
marked improvements in terms of increased
abstinence rates for opiates (specifically for
heroin and illicit methadone). The results also
show considerable reductions in the use of
illicit opiates including heroin, cocaine and
amphetamines, as well reductions in rates of
injecting and sharing needles and syringes.
Measures of physical and psychological
health and of criminal activity showed fur-
ther improvements. Detailed analyses of these
six month follow-up data are now in progress
and will be published in peer-reviewed jour-
nals in the near future. Follow-up data at 12
months from intake are now being processed,
and additional funding for NTORS has been
made available to allow continued follow-up
of the clients up to the beginning of the year
2001.
NTORS provides evidence about the pos-
sibilities for recovery among problem drug
users who seek treatment. Some traditional
views of drug addiction have taken a pessi-
mistic position on the question of outcome.
It has often been suggested that people who
become dependent upon drugs seldom give
up and that treatment has little effect. In the
first edition of the International Journal of the
Addictions, the editor stated that there is no
relationship between treatment and outcome,
the end result is that “the great majority of
addicts simply resume drug use” (Einstein,
1966). Similarly, in a review of treatment
evaluation studies, Callahan (1980) noted that
“the treatment of heroin addiction has been
singularly unsuccessful.”
Such views are not consistent with the avail-
able evidence. The large-scale treatment
outcome studies in the United States pro-
vide some of the most compelling evidence
for the possibility of recovery (Hubbard et
al., 1989; Simpson and Sells, 1990; Ball and
Ross, 1991) and there is no longer any doubt
that many addicts go on to become absti-
nent or to achieve important improvements
in their problem behaviours. In a review of
longitudinal studies of addiction careers,
Thorley (1981) concluded that there is a
gradual and steady trend towards abstinence.
In a ten-year follow-up study of a group of
heroin addicts who approached London drug
clinics in 1969, Stimson and Oppenheimer
(1982) estimated that 38% of their sample
had become abstinent. There was consider-
able evidence for the stability of abstinence.
Among the clients who had maintained ab-
stinence for nine months or more at the seven
year follow-up, the likelihood of relapse to
heroin use was rare up to the tenth year. It
was also clear that those who became absti-
nent from heroin had not, for the most part,
transferred their dependence to other sub-
stances.
These first results from NTORS provide
further support for the view that substan-
tial change, including abstinence, is a real
possibility for many people with serious
drug problems. The NTORS clients pre-
sented with a range of extremely serious,
long-standing problems. Most were physi-
cally dependent upon one or more drugs
and had been for many years. They were
experiencing a range of physical and men-
tal health problems and half of them had
experienced some sort of medical emer-
gency requiring attendance at a general
hospital Accident and Emergency Depart-
ment during the period immediately before
recruitment to NTORS. Almost one in
three of the entire cohort reported suicidal
thoughts prior to starting treatment. Many
were regularly involved in criminal
behaviours and many had previously been
in prison. It is encouraging, therefore, to
be able to report such substantial improve-
ments in key outcome measures.
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Whos asking the
question(s) and what
did they want to know?
Opiate substitution treatment for heroin de-
pendence has been considered as inappro-
priate, and less then 50 subjects were treated
by methadone up to 1993 in France. Co-
deine, available as an over-the-counter-
medication, was the only medication avail-
able for most heroin dependent subjects,
without medical or psychological support and
in a somewhat illegal status as the indication
for codeine is cough. In 1988, after an initial
experience with opium tincture (2) our group,
at the Victor Segalen University of Bordeaux
started using buprenorphine for substitution
of heroin dependent subjects seeking treat-
ment in Bayonne (6). In 1990, a retrospec-
tive evaluation of those subjects first treated
The authors alone are
responsible for the
views expressed in
this case example.
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with buprenorphine was carried out (3). This
study was extremely controversial, since the
idea of using substitution therapy was con-
sidered irrelevant by both regulatory bodies
and substance abuse therapists. Data from
the evaluation disputed this attitude, however,
this study was retrospective. This resulted in
further studies being performed involving
buprenorphine on a prospective basis. Pre-
liminary results of this ongoing prospective
research are given here.
In addition to urinalysis, a large amount of
analysis was carried out on quality of life
(QOL) issues and psychopathology to spe-
cifically attempt to address the general im-
pact of treatment and not only drug intake.
The ultimate goal for treatment of substance
abuse is to enable the patients to become
abstinent from their primary substance of
abuse, which in France is usually heroin for
opiate dependent subjects.
How were the
data collected?
All patients that began buprenorphine treat-
ment at our clinic in Bordeaux were given
the opportunity to receive a research-oriented
assessment before treatment; three and 6
months after treatment and every 6 months
thereafter (post-admission assessment: at 3,
6, 12, 18, 24 months and so on). This as-
sessment was integrated into the clinical in-
take procedure. It involved a two hour
face-to-face paper and pencil
semi-structured interview using hetero- and
auto-administered questionnaires. The instru-
ments used are presented in TABLE II.
These evaluations are part of a more com-
prehensive long term follow-up study of a
cohort of methadone and buprenorphine
maintenance treated group of opiate depen-
dent subjects looking for long term impact
of treatment and dependent predictive vari-
ables of outcome (7).
All patients were treated according to a pre-
determined protocol. Each subject was seen
on an individual basis once a week by a psy-
chiatrist specifically trained for treatment of
opioid dependent subjects with substitution
therapy. Weekly visits were
psychotherapy-oriented towards inducing
behavioural changes in patients, based on the
cognitive model and extensive collaboration
with the patient. Buprenorphine was avail-
able as sublingual 2 mg tablets. Dose was
adjusted according to patients’ use of prob-
lematic opiate (heroine, codeine, mor-
phine,...), reporting of withdrawal symptoms
and craving. Delivery of treatment was done
by a private practice pharmacist, within a non
specific pharmacy. Pharmacists received a
brief training and information on the nature
and goal of the treatment. Each patient se-
lected the pharmacist of his choice depend-
ing on proximity to home or workplace, and
on quality of rapport with the pharmacist.
Pharmacists delivered treatment on a daily
basis, 6 days out of 7. This schedule was not
changed until patient presented with three
months consecutive opiate free urine.
How were the
data analysed?
All data was treated through a data manage-
ment unit. Statistics were done with SAS
software package.
What did they find out?
Results are reported on a group of 16 sub-
jects that had completed 12 months treat-
ment in the fall of 1995. The average
buprenorphine dose at that time was 6 mg
and, due to the low dose strength of the avail-
able sublingual tablets (0.2 mg), absorption
of the medication took approximately 30
min/visit. Mean age in years at admission was
33, of which 66% were males.
This group of subjects had started treat-
ment between the beginning of 1993 and
end of 1994. During that time 19 sub-
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jects were started on buprenorphine
treatment. This results in an 84 % one
year study retention. Of the 3 subjects
that had dropped from the study, one
was deceased, one had stopped treat-
ment at the clinic and one was still in
treatment but had moved to another city.
Overall this results in a 95 % retention.
At baseline 42 % of those started on treat-
ment (8/19) were HIV positive. Within the
group that completed 12 months treatment,
50 % were HIV positive at baseline (8/16).
None of those that were negative at baseline
and completed 12 months treatment
seroconverted for HIV during that time.
The primary outcome measure assessed was
urinalysis for opiates. Abstinence was classed
as less than one opiate-positive urine sample
per month in random weekly urinalysis. Con-
sidering this group of subjects who completed
TABLE I
Instrument   Reference
DSM III-R APA, 1987 (1)
ASI McLellan, 1985 (13); Grabot, 1993 (8);
(Addiction Severity Index) Martin, 1996 (12)
TEAQV Grabot, 1996 (9, 10)
(Tableau d’évaluation assisté de la qualité de vie)
BDI Beck, 1961 (4)
(Beck Depression Inventory)
STAI Spielberger, 1970 (14); Bergeron, 1976 (5)
(Stait & Trait Anxiety Inventory)
NHP Hunt, 1980 (11)
(Nottingham Health Profile)
Urine Toxicology
TABLE II
ASI Severity Score BDI     NHP
psych med fam empl legal alcohol drug
Baseline 4,07 1,5 2,29 2,21 1,21 1,29 6,57 21 15
HIV 4,29 1 3,29 1,86 0,86 1,43 6,71 17 17
positive
HIV negative 3,86 2 1,29 2,57 1,57 1,14 6,43 24 13
12 month follow-up 2,79 1,79 1,93 1,43 0,71 0,5 1,5 14 8
HIV 2,86 2,86 1,71 1,57 0,86 0,43 1,43 16 10
positive
HIV negative 2,71 0,71 2,14 1,29 0,57 0,57 1,57 12 8
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12 months’ buprenorphine treatment, 78%
were abstinent at three months and 93% at
12 months.
Preliminary results from the ASI, BDI, and
NHP are presented in TABLE I. Results
from the TEAQV are not yet available on
that group of subjects. Results show that sub-
jects improve in most areas. This is true for
both HIV positive and negative patients.
Because the goal of treatment should not only
be to reduce symptoms, measures of quality
of life was extensive. Data from the Addic-
tion Severity Index (8, 12, 13) clearly showed
that the severity scores, measured on a scale
of 1-9 and including objective measurable
data (verifiable), subjective self-report data
(patient) and subjective report data (inter-
viewer), were lower after three months and
twelve months admission to buprenorphine
treatment as compared to before treatment.
Patients generally improved in all areas mea-
sured: psychological health, medical, family,
employment, legal, alcohol and illegal drug
use. Interestingly, patients did not switch from
heroin to alcohol, as was expected by some,
but their overall alcohol consumption actu-
ally decreased. Legal problems increased
after three months, and this was due to the
effective treatment promoting a return to ‘nor-
mal’ life: finding a permanent home and reg-
istering with local authorities, resulted in them
becoming traceable for their previous of-
fences and/or tax evasion. Quality of Life is
a global multifaceted concept that can not
be measured by only one instrument. It is
made of objective and subjective aspects, in
physical, psychological and environmental
areas. This is why we used a combination of
different instruments already available in ad-
dition to an instrument that we specifically
designed. In addition to reduction of drug
use, improvements in the more specific ar-
eas of psychopathology — depression, anxi-
ety and general health — were also noted
after 12 months.
The TEAQV (9, 10) (Tableau d’Evaluation
Assistée de la Qualité de Vie) is an instru-
ment designed to standardise the collection
of quality of life data among patients with
chronic psychiatric or somatic diseases. This
instrument is a two part, 7 point scale (0=ex-
tremely bad; 7=excellent), self-rated quanti-
tative evaluation of quality of life at different
time points in 4 areas (physical and psycho-
logical well-being, family relationships, pro-
fessional activity). The first part is a one-time
retrospective lifetime evaluation whereas the
second part is a current state evaluation that
can be prospectively repeated. Time points
are determined by important periods during
the illness or treatment course.
This instrument is administrated by a trained
interviewer in 5 to 10 minutes. The TEAQV
has been used in different populations. Our
early results with the TEAQV, suggest that it
is an easy to use and beneficial instrument
for making quality of life assessments.
Although many patients in our studies have
been shown to improve significantly in sev-
eral areas with buprenorphine treatment,
studies elsewhere have shown that many still
do not reduce their heroin intake or improve
in other areas of health. This is thought to be
due to insufficient dosing or the environment
in which treatment is given, since it is
well-known that complementary counselling
programs are also imperative for successful
rehabilitation. The conditions for treatment
efficacy also vary quite widely and can, there-
fore, be difficult to compare. Within our in-
stitution treatment protocols were strictly
standardised which is not the case elsewhere.
Patients are counselled initially and advised
that the treatment program is specifically for
the reduction of their addiction problem.
Treatment delivery is supervised daily by
pharmacists, since 90% of the French popu-
lation lives within 15 minutes walk from a
pharmacy. This enables the treatment of ad-
dicts to occur in a controlled yet unstigmatized
environment, preventing diversion of the drug
to the intravenous route and integrating the
patients into their local community.
Our feeling is that treatment outcome is de-
pendent of its control — as seen with other
treatments in psychiatry or medicine at
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large. Our group advocates that this treat-
ment should be controlled by three meth-
ods: I) extensive collaboration with the
patient, ii) use of urinalysis and iii) super-
vision of drug delivery by the local phar-
macist. Problems with patient compliance
and poor behaviour are generally not seen
with this protocol due to the time spent in
consultation with the patient, the respon-
sibility given to the patient for their reha-
bilitation and their integration into the com-
munity by daily pharmacy visits.
Results from patients treated previously
demonstrate the high retention in treatment
programs and high percentage of clean
urine. Studies considering QOL indicate
that buprenorphine treatment has more
benefit to the patient than simply switching
them from an illegal street heroin addic-
tion to a legal buprenorphine addiction.
Psychological problems, concurrent drug
use and alcohol consumption are greatly
reduced; in addition, health, social and
employment situations are improved. Pa-
tients are not constantly seeking prescrip-
tions from several clinicians, as has been
the case in the past, and the current treat-
ment program is gaining credibility with the
general public.
How did they use the
information?
In France, buprenorphine was not consid-
ered by many people in the field to be an
effective treatment. Indeed, in certain ar-
eas it was considered to be one of the pri-
mary drugs of abuse. Buprenorphine treat-
ment was considered as maintaining
subjects in addiction: switching from hero-
ine to buprenorphine was denied to be a
therapeutic action.
Following on from our studies, and oth-
ers, there was a change in French regula-
tions for treatment of substance abuse and
dependence and in February 1996, 0.4, 2
and 8 mg sublingual buprenorphine tablets
were registered in France specifically for
use in the treatment of opiate dependent
subjects.
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Its your turn
What are the strengths and the weaknesses of the presented case example? List three posi-
tive aspect and three negative aspects:
Strengths of the case study
1
2
3
Weaknesses of the case study
1
2
3
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